Novel cancer antigen and antibody for the antigen
Antibodies targeting cancer-specific proteins like XPR1 and NOX1 minimize side effects by selectively binding to cancer tissues, enhancing therapeutic efficacy while reducing normal tissue cytotoxicity.
Patent Information
- Application Number
- JP2024127667
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-01-24
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing cancer therapeutic antibodies face challenges in selectively targeting cancer cells due to antigen expression in both cancerous and normal tissues, leading to significant side effects, as they often exhibit cytotoxic activity against normal tissues despite high expression in cancer cells.
Development of antibodies that specifically bind to proteins such as XPR1, NOX1, MARVELD3 isoforms, SPINT2, MANSC1, SLC12A2, CDCP1, SEZ6L2, FLVCR1, SLC7A5, STEAP1, MMP14, TNFRSF21, and TMPRSS4, which are highly expressed in cancer tissues, particularly in colon and lung cancers with KRAS mutations, minimizing normal tissue targeting.
These antibodies provide enhanced cancer cell specificity, reducing side effects by limiting cytotoxic activity in normal tissues and increasing therapeutic efficacy against cancer cells.
Smart Images

Figure 2024156868000011 
Figure 2024156868000012 
Figure 2024156868000013
Abstract
Description
[Technical field]
[0001] The present disclosure relates to an isolated antibody that binds to or recognizes any of the following proteins: XPR1, NOX1, MARVELD3 isoform 1, MARVELD3 isoform 2, SPINT2, MANSC1, SLC12A2, CDCP1, SEZ6L2, FLVCR1, SLC7A5, STEAP1, MMP14, TNFRSF21, or TMPRSS4. [Background technology]
[0002] Antibodies are attracting attention as pharmaceuticals because they are highly stable in plasma and have few side effects. Many IgG-type antibody drugs are on the market, and many antibody drugs are currently being developed (Non-Patent Document 1, Non-Patent Document 2).
[0003] As cancer therapeutic drugs using antibody drugs, Rituxan against CD20 antigen, Cetuximab against EGFR antigen, Herceptin against HER2 antigen, etc. have been approved (Non-Patent Document 3). These antibody molecules bind to antigens expressed in cancer cells and exert cytotoxic activity against cancer cells by ADCC activity, etc. It is known that such cytotoxic activity due to ADCC activity, etc. depends on the number of antigens expressed in the target cells of the therapeutic antibody (Non-Patent Document 4), so from the viewpoint of the effect of the therapeutic antibody, it is preferable that the expression amount of the target antigen is high. However, even if the expression amount of the antigen is high, if the antigen is expressed in normal tissue, it will exert cytotoxic activity such as ADCC activity against normal cells, and side effects become a major problem. Therefore, it is preferable that the antigen targeted by the therapeutic antibody as a cancer therapeutic drug is specifically expressed in cancer cells. For example, antibody molecules against the EpCAM antigen, which is known as a cancer antigen, were thought to be promising as cancer treatment drugs, but the EpCAM antigen is also known to be expressed in the pancreas, and in fact, in clinical trials, it has been reported that administration of anti-EpCAM antibodies causes the side effect of pancreatitis due to cytotoxic activity against the pancreas (Non-Patent Document 5).
[0004] Following the success of antibody drugs that exert cytotoxic activity through ADCC activity, improved second-generation antibody molecules that exert strong cytotoxic activity have been reported by enhancing ADCC activity by removing fucose from the N-glycosylated Fc region of natural human IgG1 (Non-Patent Document 6), enhancing ADCC activity by enhancing binding to FcγRIIIa through amino acid substitution in the Fc region of natural human IgG1 (Non-Patent Document 7), etc. As antibody drugs that exert cytotoxic activity against cancer cells by a mechanism other than the above-mentioned NK cell-mediated ADCC activity, improved antibody molecules that exert stronger cytotoxic activity, such as antibody drug conjugates (ADCs) in which a drug with strong cytotoxic activity is conjugated to an antibody (Non-Patent Document 8), and low-molecular-weight antibodies that exert cytotoxic activity against cancer cells by recruiting T cells to the cancer cells (Non-Patent Document 9), have also been reported.
[0005] Such antibody molecules that exert stronger cytotoxic activity can exert cytotoxic activity against cancer cells that do not express many antigens, while exerting cytotoxic activity against normal tissues that express few antigens in the same way as cancer cells. In fact, compared with cetuximab, which is a natural human IgG1 against the EGFR antigen, EGFR-BiTE, a bispecific antibody against CD3 and EGFR, can exert strong cytotoxic activity against cancer cells and exert antitumor effects by recruiting T cells to cancer cells. On the other hand, since EGFR is also expressed in normal tissues, it has been observed that serious side effects occur when EGFR-BiTE is administered to cynomolgus monkeys (Non-Patent Document 10). In addition, bivatuzumab mertansine, an ADC in which mertansine is bound to an antibody against CD44v6, which is highly expressed in cancer cells, has been observed to cause severe skin toxicity and liver toxicity in clinical trials because CD44v6 is also expressed in normal tissues (Non-Patent Document 11).
[0006] When using an antibody that can exert a strong cytotoxic activity against cancer cells with low antigen expression, the target antigen must be expressed in an extremely cancer-specific manner, but the number of cancer antigens that are expressed in an extremely cancer-specific manner is thought to be limited, as seen in the fact that HER2, the target antigen of Herceptin, and EGFR, the target antigen of Cetuximab, are also expressed in normal tissues. Therefore, although the cytotoxic activity against cancer can be strengthened, side effects due to cytotoxicity against normal tissues can become a problem.
[0007] Various technologies applicable to second-generation antibody drugs have been developed, and technologies for improving effector function, antigen-binding ability, pharmacokinetics, and stability, or for reducing the risk of immunogenicity have been reported (Non-Patent Document 12). However, in order to resolve the above-mentioned side effects and enable antibody drugs to act specifically on target cancer tissues, there remains a need to identify antigens that are hardly or only weakly expressed in normal tissues and are specifically expressed in cancer cells. [Prior art documents] [Non-patent literature]
[0008] [Non-Patent Document 1] Monoclonal antibody successes in the clinic. Janice M Reichert, Clark J Rosensweig, Laura B Faden & Matthew C Dewitz, Nat. Biotechnol. (2005) 23, 1073 - 1078 [Non-Patent Document 2] The therapeutic antibodies market to 2008. Pavlou AK, Belsey MJ., Eur. J. Pharm. Biopharm. (2005) 59 (3), 389-396 [Non-Patent Document 3] Monoclonal antibodies: versatile platforms for cancer immunotherapy. Weiner LM, Surana R, Wang S., Nat. Rev. Fr. Immunol. (2010) 10(5), 317–3
Outdoor Tools 4
Direct Environment 5
Outdoor Configuration 6
Direct Environment 7
Non-Patent Document 8
Non-Patent Document 9
Non-Patent Document 10
Non-Patent Document 11
[0009] The invention disclosed herein has been made in consideration of the above-mentioned circumstances, and aims to provide, in one non-limiting aspect, an antibody that binds to or recognizes an antigen that is hardly or only slightly expressed in normal tissues and is specifically highly expressed in cancer cells. [Means for solving the problem]
[0010] In a non-limiting embodiment, the present inventors have found, as a result of intensive research, XPR1, NOX1, MARVELD3 isoform 1, MARVELD3 isoform 2, SPINT2, MANSC1, SLC12A2, CDCP1, SEZ6L2, FLVCR1, SLC7A5, STEAP1, MMP14, TNFRSF21, and TMPRSS4 as cell surface proteins whose protein expression is high in cancer tissues and low in adjacent normal tissues and normal tissues. The present inventors have also found that these proteins are highly cancer-specific antigens that are highly expressed in colon cancer tissues (particularly colon cancer tissues with KRAS mutations) and / or lung cancer tissues.
[0011] The present disclosure is based on such findings and specifically includes the embodiments exemplified below. [1] An isolated antibody that binds to any of the following proteins: XPR1, NOX1, MARVELD3 isoform 1, MARVELD3 isoform 2, SPINT2, MANSC1, SLC12A2, CDCP1, SEZ6L2, FLVCR1, SLC7A5, STEAP1, MMP14, TNFRSF21, TMPRSS4. [2] The antibody described in [1] that binds to the extracellular domain of the protein. [3] (1) XPR1 represented by SEQ ID NO: 1, (2) NOX1 represented by SEQ ID NO: 2, (3) MARVELD3 isoform 1 represented by SEQ ID NO: 3, (4) MARVELD3 isoform 2 represented by SEQ ID NO: 4, (5) SPINT2 represented by SEQ ID NO: 5, (6) MANSC1 represented by SEQ ID NO: 7, (7) SLC12A2 represented by SEQ ID NO: 8, (8) CDCP1 represented by SEQ ID NO: 9, (9) SEZ6L2 represented by SEQ ID NO: 12, (10) FLVCR1 represented by SEQ ID NO: 13, (11) SLC7A5 represented by SEQ ID NO: 14, (12) STEAP1 represented by SEQ ID NO: 15, (13) MMP14 represented by SEQ ID NO: 16, (14) TNFRSF21 represented by SEQ ID NO: 17, and (15) TMPRSS4 represented by SEQ ID NO: 18 The antibody according to [1] or [2], which binds to either of the above. [4] (1) The following in the amino acid sequence shown in SEQ ID NO:1: Amino acids 1 to 108, 111 to 122, 159 to 171, 177 to 216, 423 to 448, 473 to 502, 660 to 670, 674 to 696, 177 to 190, 428 to 448, 660 to 670, 244, 256 to 273, 257 to 270, 258 to 264, 258 to 268, 256 to 270, 258 to 273, 260 to 270, 293 to 314, 336 to 343, 337 to 344, 338 to 341, 340 342nd, 340th to 344th, 343rd to 344th, 340th to 345th, 368th to 372nd, 392nd to 398th, 397th to 401st, 398th to 402nd, 420th to 442nd, 420th to 506th, 465th to 479th, 497th to 507th, 498th to 508th, 529th to 555th, 529th to 570th, 582nd to 586th, 1st to 234th, 1st to 236th, 293rd to 318th, 367th to 442nd, 369th to 473rd, 500th to 507th, 529th to 696th, 589th to 696th the extracellular domain of XPR1, (2) the amino acid sequence shown in SEQ ID NO: 2, Amino acids 44 to 54, 131 to 161, 242 to 258, 1 to 4, 1 to 11, 18 to 55, 28 to 44, 31 to 44, 32 to 46, 34 to 50, 70 to 102, 70 to 103, 117 to 176, 120 to 172, 122 to 166, 122 to 172, 124 to 168, 190 to 208, 191 to 204, 223 to 266, 223 to 267, 227 to 269, 228 to 391, 228 to 396, 404, 420 to 564 the extracellular domain of NOX1, (3) the amino acid sequence shown in SEQ ID NO: 3, Amino acids 222 to 266, 223 to 269, 227 to 264, 227 to 268, 229 to 263, 231 to 265, 321 to 362, 322 to 357, 323 to 357, 324 to 357, and 324 to 358 the extracellular domain of MARVELD3 isoform 1, (4) the amino acid sequence shown in SEQ ID NO: 4, Amino acids 101 to 111, 163 to 198, 1 to 266, 1 to 270, 216 to 271, 222 to 269, 226 to 271, 227 to 268, 227 to 271, 248 to 271, 316 to 364, 322 to 360, 323 to 359, 324 to 360, 326 to 360, 327 to 360 The extracellular domain of MARVELD3 isoform 2, which is either The antibody according to [1] or [2], which binds to either of the above. [4A] The antibody according to any one of [1], [2], [3](1), and [4](1), which is capable of binding to XPR1, and is selected from the group consisting of: (a1) an antibody comprising HVR-H1 consisting of the amino acid sequence of SEQ ID NO: 35, HVR-H2 consisting of the amino acid sequence of SEQ ID NO: 36, HVR-H3 consisting of the amino acid sequence of SEQ ID NO: 37, HVR-L1 consisting of the amino acid sequence of SEQ ID NO: 38, HVR-L2 consisting of the amino acid sequence of SEQ ID NO: 39, and HVR-L3 consisting of the amino acid sequence of SEQ ID NO: 40; (a2) an antibody comprising the VH sequence of SEQ ID NO: 41 and the VL sequence of SEQ ID NO: 42; (a3) an antibody that binds to the same epitope in XPR1 as any one of the antibodies (a1) to (a2); (a4) an antibody that competes with the binding of any one of the antibodies (a1) to (a2) to XPR1; (a5) an antibody that inhibits the binding of any one of the antibodies (a1) to (a2) to XPR1 by 50% or more in a competitive assay; (a6) an antibody comprising a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 41 and a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 42; An antibody selected from the group consisting of [4B] The antibody according to any one of [1], [2], [3](2), and [4](2), which is capable of binding to NOX1, and which is one of the following: (b1) an antibody comprising HVR-H1 consisting of the amino acid sequence of SEQ ID NO: 67, HVR-H2 consisting of the amino acid sequence of SEQ ID NO: 68, HVR-H3 consisting of the amino acid sequence of SEQ ID NO: 69, HVR-L1 consisting of the amino acid sequence of SEQ ID NO: 70, HVR-L2 consisting of the amino acid sequence of SEQ ID NO: 71, and HVR-L3 consisting of the amino acid sequence of SEQ ID NO: 72; (b2) an antibody comprising HVR-H1 consisting of the amino acid sequence of SEQ ID NO: 75, HVR-H2 consisting of the amino acid sequence of SEQ ID NO: 76, HVR-H3 consisting of the amino acid sequence of SEQ ID NO: 77, HVR-L1 consisting of the amino acid sequence of SEQ ID NO: 78, HVR-L2 consisting of the amino acid sequence of SEQ ID NO: 79, and HVR-L3 consisting of the amino acid sequence of SEQ ID NO: 80; (b3) an antibody comprising the VH sequence of SEQ ID NO: 73 and the VL sequence of SEQ ID NO: 74; (b4) an antibody comprising the VH sequence of SEQ ID NO: 81 and the VL sequence of SEQ ID NO: 82; (b5) an antibody that binds to the same epitope in NOX1 as any one of the antibodies (b1) to (b4); (b6) an antibody that competes with the binding of any one of the antibodies (b1) to (b4) to NOX1; (b7) an antibody that inhibits the binding of any one of the antibodies (b1) to (b4) to NOX1 by 50% or more in a competitive assay; (b8) an antibody comprising a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 73 and a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 74; (b9) an antibody comprising a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 81 and a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 82; An antibody selected from the group consisting of [4C] The antibody according to any one of [1], [2], [3](3), [3](4), [4](3), and [4](4), which is capable of binding to MARVELD3 isoform 1 and / or MARVELD3 isoform 2, and is selected from the group consisting of: (c1) an antibody comprising HVR-H1 consisting of the amino acid sequence of SEQ ID NO: 43, HVR-H2 consisting of the amino acid sequence of SEQ ID NO: 44, HVR-H3 consisting of the amino acid sequence of SEQ ID NO: 45, HVR-L1 consisting of the amino acid sequence of SEQ ID NO: 46, HVR-L2 consisting of the amino acid sequence of SEQ ID NO: 47, and HVR-L3 consisting of the amino acid sequence of SEQ ID NO: 48; (c2) an antibody comprising HVR-H1 consisting of the amino acid sequence of SEQ ID NO: 51, HVR-H2 consisting of the amino acid sequence of SEQ ID NO: 52, HVR-H3 consisting of the amino acid sequence of SEQ ID NO: 53, HVR-L1 consisting of the amino acid sequence of SEQ ID NO: 54, HVR-L2 consisting of the amino acid sequence of SEQ ID NO: 55, and HVR-L3 consisting of the amino acid sequence of SEQ ID NO: 56; (c3) an antibody comprising the VH sequence of SEQ ID NO: 49 and the VL sequence of SEQ ID NO: 50; (c4) an antibody comprising the VH sequence of SEQ ID NO: 57 and the VL sequence of SEQ ID NO: 58; (c5) an antibody that binds to the same epitope in MARVELD3 isoform 1 and / or MARVELD3 isoform 2 as any one of the antibodies (c1) to (c4); (c6) an antibody that competes with the binding of any one of the antibodies (c1) to (c4) to MARVELD3 isoform 1 and / or MARVELD3 isoform 2; (c7) an antibody that inhibits the binding of any one of antibodies (c1) to (c4) to MARVELD3 isoform 1 and / or MARVELD3 isoform 2 by 50% or more in a competitive assay; (c8) an antibody comprising a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 49 and a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 50; (c9) an antibody comprising a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 57 and a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 58; An antibody selected from the group consisting of [5] An antibody described in any one of [1] to [4C], which has cytotoxic activity. [6] An antibody described in any one of [1] to [5], which has internalizing activity. [7] An antibody described in any one of [1] to [6], which is a monoclonal antibody. [8] An antibody described in any one of [1] to [7], which is a human antibody, a humanized antibody, or a chimeric antibody. [9] An antibody described in any one of [1] to [8], which is an antibody fragment.
[10] An antibody described in any one of [1] to [8], which is a full-length IgG antibody.
[11] The antibody described in any one of [1] to
[10] , which is a multispecific antibody.
[12] The antibody described in
[11] , further comprising a T cell receptor complex binding domain.
[13] The antibody described in
[11] or
[12] , wherein the multispecific antibody contains one binding domain for the protein.
[14] An antibody described in any one of
[11] to
[13] , which comprises an Fc region having reduced binding activity to Fcγ receptors.
[15] The antibody described in
[14] , wherein the Fc region has lower Fcγ receptor binding activity than the Fc region of IgG1, IgG2, IgG3, or IgG4.
[16] The antibody described in
[12] or
[15] above, wherein the antibody has cytotoxic activity, and the cytotoxic activity is T cell-dependent cytotoxic activity.
[17] An antibody described in any one of
[12] to
[16] , wherein the T cell receptor complex binding domain is a T cell receptor binding domain having binding activity to a T cell receptor.
[18] An antibody described in any one of
[12] to
[16] , wherein the T cell receptor complex binding domain is a CD3 binding domain having binding activity to CD3.
[19] The antibody described in
[18] , wherein the CD3 binding domain is capable of binding to the CD3ε chain.
[20] An antibody described in
[18] or
[19] , wherein the CD3 binding domain is a domain containing an antibody heavy chain variable region and an antibody light chain variable region. [20A] The CD3 binding domain may be: (d1) a domain comprising an antibody variable region having HVR-H1 consisting of the amino acid sequence of SEQ ID NO: 59, HVR-H2 consisting of the amino acid sequence of SEQ ID NO: 60, HVR-H3 consisting of the amino acid sequence of SEQ ID NO: 61, HVR-L1 consisting of the amino acid sequence of SEQ ID NO: 62, HVR-L2 consisting of the amino acid sequence of SEQ ID NO: 63, and HVR-L3 consisting of the amino acid sequence of SEQ ID NO: 64; (d2) a domain comprising an antibody variable region having the VH sequence of SEQ ID NO: 65 and the VL sequence of SEQ ID NO: 66; (d3) a domain comprising an antibody variable region that binds to the same epitope in CD3 as any one of the antibody variable regions (d1) to (d2); (d4) a domain comprising an antibody variable region that competes with the binding to CD3 of any one of the antibody variable regions (d1) to (d2); (d5) a domain containing an antibody variable region that inhibits the binding to CD3 of any one of the antibody variable regions (d1) to (d2) by 50% or more in a competitive assay; (d6) a domain comprising an antibody variable region having a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 65 and a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 66; The antibody according to any one of
[18] to
[20] , selected from the group consisting of:
[21] The antibody described in any one of
[11] to [20A], wherein the multispecific antibody is a bispecific antibody.
[22] An isolated nucleic acid encoding an antibody described in any one of [1] to
[21] .
[23] A host cell comprising the nucleic acid described in
[22] .
[24] A method for producing an antibody according to any one of [1] to
[21] , comprising culturing a host cell according to
[23] so as to produce the antibody.
[25] The method according to
[24] , further comprising the step of recovering the antibody from the host cell.
[26] An immunoconjugate comprising an antibody described in any one of [1] to
[21] and a cytotoxic agent.
[27] A pharmaceutical formulation comprising an antibody described in any one of [1] to
[21] and a pharma- ceutically acceptable carrier.
[28] An antibody described in any one of [1] to
[21] for use as a pharmaceutical.
[29] An antibody described in any one of [1] to
[21] for use in the treatment of cancer.
[30] The antibody described in
[29] , wherein the cancer is lung cancer, and the antibody binds to any of XPR1, SPINT2, SEZ6L2, FLVCR1, SLC7A5, STEAP1, MMP14, TNFRSF21, and TMPRSS4.
[31] The antibody described in
[30] , wherein the lung cancer does not have one or more selected from EGFR driver mutations, BRAF driver mutations, ERBB2 driver mutations, ALK fusion gene expression, and RET / ROS1 fusion gene expression.
[32] The antibody described in
[30] or
[31] , wherein the lung cancer is lung adenocarcinoma.
[33] The antibody described in
[29] , wherein the cancer is colorectal cancer, and the antibody binds to any of NOX1, MARVELD3 isoform 1, MARVELD3 isoform 2, SPINT2, MANSC1, SLC12A2, or CDCP1.
[34] The antibody described in
[33] , wherein the colorectal cancer is colorectal cancer having a KRAS mutation.
[35] An antibody described in any one of [1] to
[21] for use in inducing cytotoxic activity.
[36] Use of an antibody described in any one of [1] to
[21] in the manufacture of a pharmaceutical product.
[37] Use of an antibody described in any one of [1] to
[21] in the manufacture of a pharmaceutical for cancer treatment.
[38] The use described in
[37] , wherein the cancer is lung cancer, and the antibody binds to any of XPR1, SPINT2, SEZ6L2, FLVCR1, SLC7A5, STEAP1, MMP14, TNFRSF21, and TMPRSS4.
[39] The use described in
[38] , wherein the lung cancer does not have one or more selected from EGFR driver mutations, BRAF driver mutations, ERBB2 driver mutations, ALK fusion gene expression, and RET / ROS1 fusion gene expression.
[40] The use described in
[38] or
[39] , wherein the lung cancer is lung adenocarcinoma.
[41] The use described in
[37] , wherein the cancer is colorectal cancer, and the antibody binds to any of NOX1, MARVELD3 isoform 1, MARVELD3 isoform 2, SPINT2, MANSC1, SLC12A2, or CDCP1.
[42] The use described in
[41] , wherein the colorectal cancer is colorectal cancer having a KRAS mutation.
[43] Use of an antibody described in any one of [1] to
[21] in the manufacture of a pharmaceutical agent for inducing cytotoxic activity.
[44] A method for treating an individual having cancer, comprising administering to the individual an effective amount of an antibody described in any one of [1] to
[21] .
[45] The method described in
[44] , wherein the cancer is lung cancer, and the antibody binds to any of XPR1, SPINT2, SEZ6L2, FLVCR1, SLC7A5, STEAP1, MMP14, TNFRSF21, and TMPRSS4.
[46] The method described in
[45] , wherein the lung cancer does not have one or more selected from EGFR driver mutations, BRAF driver mutations, ERBB2 driver mutations, ALK fusion gene expression, and RET / ROS1 fusion gene expression.
[47] The method according to
[45] or
[46] , wherein the lung cancer is lung adenocarcinoma.
[48] The method described in
[44] , wherein the cancer is colorectal cancer and the antibody binds to any of NOX1, MARVELD3 isoform 1, MARVELD3 isoform 2, SPINT2, MANSC1, SLC12A2, or CDCP1.
[49] The method according to
[48] , wherein the colorectal cancer is colorectal cancer having a KRAS mutation.
[50] A method for inducing cytotoxic activity in an individual, the method comprising the step of administering to the individual an effective amount of an antibody described in any one of [1] to
[21] to induce cytotoxic activity.
[51] A method for detecting the presence of XPR1, NOX1, MARVELD3 isoform 1, MARVELD3 isoform 2, SPINT2, MANSC1, SLC12A2, CDCP1, SEZ6L2, FLVCR1, SLC7A5, STEAP1, MMP14, TNFRSF21, or TMPRSS4 in a biological sample, comprising contacting an antibody described in any one of [1] to
[21] that is capable of binding to the protein to be detected with the biological sample under conditions that permit binding to the protein to be detected.
[52] A method for detecting cancer cells in a biological sample, comprising contacting an antibody described in any one of [1] to
[21] with the biological sample under conditions that allow binding of the antibody to a protein that is an antigen of the antibody.
[53] A method for detecting colorectal cancer cells in a biological sample, comprising contacting an antibody described in any one of [1] to
[21] capable of binding to NOX1, MARVELD3 isoform 1, MARVELD3 isoform 2, SPINT2, MANSC1, SLC12A2, or CDCP1 with the biological sample under conditions that allow binding of the antibody to a protein that is an antigen of the antibody.
[54] A method for detecting colorectal cancer cells having a KRAS mutation in a biological sample, comprising contacting an antibody described in any one of [1] to
[21] that is capable of binding to NOX1, MARVELD3 isoform 1, MARVELD3 isoform 2, SPINT2, MANSC1, SLC12A2, or CDCP1 with the biological sample under conditions that allow binding of the antibody to a protein that is an antigen of the antibody.
[55] A method for detecting lung cancer cells in a biological sample, comprising contacting an antibody described in any one of [1] to
[21] capable of binding to XPR1, SPINT2, SEZ6L2, FLVCR1, SLC7A5, STEAP1, MMP14, TNFRSF21, or TMPRSS4 with the biological sample under conditions that allow binding of the antibody to a protein that is an antigen of the antibody.
[56] A method for detecting lung cancer cells in a biological sample that do not have one or more selected from EGFR driver mutations, BRAF driver mutations, ERBB2 driver mutations, ALK fusion gene expression, and RET / ROS1 fusion gene expression, comprising contacting the biological sample with an antibody described in any one of [1] to
[21] that is capable of binding to XPR1, SPINT2, SEZ6L2, FLVCR1, SLC7A5, STEAP1, MMP14, TNFRSF21, or TMPRSS4 under conditions that allow binding of the antibody to a protein that is an antigen of the antibody. [Brief description of the drawings]
[0012] [Figure 1-1] This shows the protein expression of each target antigen candidate. The vertical axis shows the molecule name and the quantitative value of protein expression (iBAQ value), and the horizontal axis shows the analyzed tissue. All LC-MS data (N=3) of all samples derived from each tissue are plotted. ● indicates a sample with a KRAS mutation in colon cancer tissue and a sample with a driver mutation in lung cancer tissue, and ○ indicates a sample without the aforementioned mutation. [Figure 1-2] See description of Figure 1-1. [Figure 1-3] See description of Figure 1-1. [Figure 1-4] See description of Figure 1-1. [Figure 1-5] See description of Figure 1-1. [Figure 1-6] See description of Figure 1-1. [Figure 1-7] See description of Figure 1-1. [Figure 1-8] See description of Figure 1-1. [Figure 1-9] See description of Figure 1-1. [Figure 1-10] See description of Figure 1-1. [Figure 1-11] See description of Figure 1-1. [Figure 1-12] See description of Figure 1-1. [Figure 1-13] See description of Figure 1-1. [Figure 1-14] See description of Figure 1-1. [Figure 1-15] See description of Figure 1-1. [Figure 1-16] See description of Figure 1-1. [Diagram 2] This figure shows an alignment of the amino acid sequences of MARVELD3 isoforms 1 and 2 (SEQ ID NOs: 3 and 4, respectively). Based on Fig. 1A of Raleigh DR et al., Mol. Biol. Cell 21, 2010, the extracellular domain is underlined. [Figure 3-1] Comparison of expression levels of MARVELD3 isoform 1 and 2 specific peptides in colon cancer samples. Figure 3-1 shows the expression levels of MARVELD3 isoform 2, and Figure 3-2 shows the expression levels of MARVELD3 isoform 1. Since EKPAEMFEF was identified as an isoform 2 specific peptide and QLDQQYTILR was identified as an isoform 1 specific peptide, the expression levels were compared based on the signal intensity of these peptides. The vertical axis shows the signal intensity of isoform 1 and 2 specific peptides, and the horizontal axis shows the sample names of colon cancer and adjacent normal tissues (LC-MS analysis was performed for each sample with N=3). Black bars show samples with KRAS mutations, and gray bars show samples without KRAS mutations. [Figure 3-2] See description of Figure 3-1. [Figure 4-1]This figure shows the results of cell surface localization analysis of XPR1, NOX1, and MARVELD3 isoform 2 (SEQ ID NOs: 1, 2, and 4, respectively). In the total amino acid sequence of each protein, the transmembrane domain in the uniprot Topology information is enclosed in a single line box, and the extracellular domain is enclosed in a double line box. The dotted lines indicate peptides identified in overexpressing cells, and the parts with black underlined and bold amino acids indicate peptides identified from endogenous proteins. [Figure 4-2] See description of Figure 4-1. [Figure 4-3] See description of Figure 4-1. [Figure 5-1] FIG. 1 shows the expression levels of XPR1 in NCI-H2227 cells and HLC-1 cells. [Figure 5-2] FIG. 1 shows the expression level of MARVELD3 isoform2 in Caco-2 cells. [Figure 6] FIG. 1 shows Alexa488 staining of a fraction stained with CellTrace FarRed (cells into which an empty plasmid vector was introduced) and a fraction not stained with CellTrace FarRed (cells into which a human XPR1-Myc expression plasmid vector was introduced). [Figure 7] FIG. 1 shows the cell proliferation inhibition rate of anti-human XPR1 / anti-human CD3 bispecific antibodies. [Figure 8] FIG. 1 shows the cell proliferation inhibition rate of anti-human XPR1 / anti-human CD3 bispecific antibodies. [Figure 9] FIG. 1 shows Alexa488 staining of a fraction stained with CellTrace FarRed (cells into which an empty plasmid vector was introduced) and a fraction not stained with CellTrace FarRed (cells into which a human MARVELD3 isoform2-expressing plasmid vector was introduced). [Figure 10] FIG. 1 shows the cell proliferation inhibition rate of anti-human MARVELD3 isoform 2 / anti-human CD3 bispecific antibodies. [Figure 11]This figure shows Alexa488 staining of a fraction that was not stained with CellTrace FarRed and CellTrace Violet (human NOX1-Strep-transfected cells), a fraction that was stained with CellTrace FarRed and CellTrace Violet (NOX1_Nx1B_564-myc-transfected cells), and a fraction that was stained only with CellTrace FarRed (cells transfected with an empty plasmid vector). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0013] I. Definition The term "anti-target protein antibody" or "antibody that binds to a target protein" refers to an antibody that can bind to a target protein with sufficient affinity such that the antibody is useful as a diagnostic and / or therapeutic agent when targeted to the target protein. In one embodiment, the extent of binding of an anti-target protein antibody to an unrelated, non-target protein is less than about 10% of the binding of the antibody to the target protein as measured (e.g., by radioimmunoassay (RIA)). In certain embodiments, an antibody that binds to a target protein has an affinity of ≦1 μM, ≦100 nM, ≦10 nM, ≦1 nM, ≦0.1 nM, ≦0.01 nM, or ≦0.001 nM (e.g., 10 -8 M or less, e.g. 10 -8 M~10 -13 M, for example, 10 -9 M~10 -13 In certain embodiments, the anti-target protein antibody binds to an epitope of the target protein that is conserved among target proteins from different species.
[0014] "Affinity" refers to the strength of the total non-covalent interactions between one binding site of a molecule (e.g., an antibody) and the molecule's binding partner (e.g., an antigen). Unless otherwise indicated, "binding affinity" as used herein refers to the inherent binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X for its partner Y can generally be expressed by the dissociation constant (Kd). Affinity can be measured by conventional methods known in the art, including those described herein. Specific illustrative and exemplary embodiments for measuring binding affinity are described below.
[0015] "Percent (%) amino acid sequence identity" to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to amino acid residues in the reference polypeptide sequence after aligning the sequences to obtain the maximum percent sequence identity and introducing gaps if necessary, and not considering any conservative substitutions as part of the sequence identity. Alignment for the purpose of determining percent amino acid sequence identity can be achieved by various methods within the skill of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, Megalign (DNASTAR) software, or GENETYX (registered trademark) (Genetyx Co., Ltd.). Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms required to achieve maximum alignment over the entire length of the sequences being compared.
[0016] The ALIGN-2 sequence comparison computer program is the copyright of Genentech, Inc., and its source code has been filed with user documentation in the US Copyright Office, Washington DC, 20559, where it is registered under US Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or may be compiled from the source code. The ALIGN-2 program is compiled for use on UNIX operating systems, including Digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary. In the context of using ALIGN-2 for amino acid sequence comparison, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (alternatively, one may say a given amino acid sequence A has or contains a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows: 100 times the fraction X / Y, where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in said program's alignment of A and B, and Y is the total number of amino acid residues in B. It will be understood that if the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B is not equal to the % amino acid sequence identity of B to A. Unless otherwise specified, all % amino acid sequence identity values used herein are obtained using the ALIGN-2 computer program as described in the immediately preceding paragraph.
[0017] The term "antibody" is used herein in the broadest sense and encompasses a variety of antibody structures, including, but not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, so long as they exhibit the desired antigen-binding activity.
[0018] An "antibody fragment" refers to a molecule other than a complete antibody that contains a portion of the complete antibody that binds to the antigen to which the complete antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab') 2 linear antibodies; single-chain antibody molecules (eg, scFv); and multispecific antibodies formed from antibody fragments (multispecific antibodies).
[0019] The terms "full length antibody," "complete antibody," and "whole antibody" are used interchangeably herein and refer to an antibody having a structure substantially similar to a native antibody structure or having a heavy chain that includes an Fc region as defined herein.
[0020] "Native antibodies" refer to immunoglobulin molecules with various structures that occur naturally. For example, native IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons composed of two identical light chains and two identical heavy chains that are disulfide-bonded. From the N-terminus to the C-terminus, each heavy chain has a variable region (VH), also called the variable heavy domain or the heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3). Similarly, from the N-terminus to the C-terminus, each light chain has a variable region (VL), also called the variable light domain or the light chain variable domain, followed by a constant light (CL) domain. The light chain of an antibody may be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of its constant domain.
[0021] The term "variable region" or "variable domain" refers to the domain of an antibody's heavy or light chain that is involved in binding the antibody to an antigen. The heavy and light chain variable domains (VH and VL, respectively) of natural antibodies usually have a similar structure, with each domain containing four conserved framework regions (FR) and three hypervariable regions (HVR). (See, for example, Kindt et al. Kuby Immunology, 6th ed., WH Freeman and Co., page 91 (2007).) One VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind to a particular antigen may be isolated by screening a complementary library of VL or VH domains, respectively, with a VH or VL domain from an antibody that binds to the antigen. See, e.g., Portolano et al., J. Immunol. 150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991).
[0022] The term "hypervariable region" or "HVR" as used herein refers to each region of an antibody variable domain that is hypervariable in sequence (the "complementarity determining region" or "CDR") and / or forms structurally defined loops (the "hypervariable loops") and / or contains antigen contact residues (the "antigen contacts"). Typically, antibodies contain six HVRs: three in the VH (H1, H2, H3) and three in the VL (L1, L2, L3). Exemplary HVRs herein include the following: (a) hypervariable loops occurring at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)); (b) CDRs occurring at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991)); (c) antigenic contacts occurring at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al. J. Mol. Biol. 262: 732-745 (1996)); and (d) combinations of (a), (b), and / or (c), comprising HVR amino acid residues 46-56 (L2), 47-56 (L2), 48-56 (L2), 49-56 (L2), 26-35 (H1), 26-35b (H1), 49-65 (H2), 93-102 (H3), and 94-102 (H3). Unless otherwise indicated, HVR residues and other residues in the variable domain (eg, FR residues) are numbered herein according to Kabat et al., supra.
[0023] "Framework" or "FR" refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain typically consists of four FR domains: FR1, FR2, FR3, and FR4. Accordingly, the HVR and FR sequences typically appear in VH (or VL) in the following order: FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.
[0024] The term "Fc region" is used herein to define a C-terminal region of an immunoglobulin heavy chain that includes at least a portion of the constant region. This term includes native sequence Fc regions and variant Fc regions. In one embodiment, a human IgG heavy chain Fc region extends from Cys226 or from Pro230 to the carboxyl terminus of the heavy chain, except that the C-terminal lysine (Lys447) or glycine-lysine (Gly446-Lys447) of the Fc region may or may not be present. Unless otherwise specified herein, the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system (also referred to as the EU index) as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD 1991.
[0025] A "functional Fc region" comprises an "effector function" of a native sequence Fc region. Exemplary "effector functions" include C1q binding; CDC; Fc receptor binding; ADCC; phagocytosis; downregulation of cell surface receptors (e.g., B cell receptor (BCR)); and the like. Such effector functions generally require that the Fc region be combined with a binding domain (e.g., an antibody variable domain) and may be assessed using a variety of assays, e.g., as disclosed within the definitions herein.
[0026] The "class" of an antibody refers to the type of constant domain or constant region present in the antibody's heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM. Some of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.
[0027] A "human antibody" is an antibody with an amino acid sequence that corresponds to that of an antibody produced by a human or a human cell, or derived from a human antibody repertoire or other non-human source that uses human antibody coding sequences. This definition of a human antibody specifically excludes humanized antibodies, which contain non-human antigen-binding residues.
[0028] A "humanized" antibody refers to a chimeric antibody that contains amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody contains substantially all of at least one, and typically two, variable domains, in which all or substantially all HVRs (e.g., CDRs) correspond to those of a non-human antibody and all or substantially all FRs correspond to those of a human antibody. A humanized antibody may optionally contain at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody (e.g., a non-human antibody) refers to an antibody that has undergone humanization.
[0029] The term "chimeric" antibody refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.
[0030] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a population of substantially homogeneous antibodies. That is, the individual antibodies comprising the population are identical and / or bind to the same epitope, except for possible variants (e.g., variants including naturally occurring variants or variants that arise during the manufacture of a monoclonal antibody preparation; such variants are usually present in small amounts). In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier "monoclonal" indicates the character of the antibody as being obtained from a population of substantially homogeneous antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies to be used in accordance with the present disclosure may be made by a variety of techniques, including, but not limited to, hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals that contain all or part of the human immunoglobulin loci; such methods and other exemplary methods for making monoclonal antibodies are described herein.
[0031] An "antibody that binds to the same epitope" as a reference antibody refers to an antibody that blocks the binding of the reference antibody to its own antigen by 50% or more in a competitive assay, and conversely, the reference antibody blocks the binding of the antibody to its own antigen by 50% or more in a competitive assay. Exemplary competitive assays are provided herein.
[0032] In an exemplary competitive assay, an immobilized target antigen (XPR1, NOX1, MARVELD3 isoform 1, MARVELD3 isoform 2, SPINT2, MANSC1, SLC12A2, CDCP1, SEZ6L2, FLVCR1, SLC7A5, STEAP1, MMP14, TNFRSF21, or TMPRSS4) is incubated in a solution containing a first labeled antibody (e.g., XPB0062, NXA0125, NXA0164, MDA0279, or MDA0314) that binds to the target antigen and a second unlabeled antibody that is tested for its ability to compete with the first antibody for binding to the target antigen. The second antibody may be present in a hybridoma supernatant. As a control, the immobilized target antigen is incubated in a solution containing the first labeled antibody but not the second unlabeled antibody. After incubation under conditions that permit binding of the first antibody to the target antigen, excess unbound antibody is removed and the amount of label bound to the immobilized target antigen is measured. If the amount of label bound to the immobilized target antigen is substantially reduced in the test sample compared to the control sample, it indicates that the second antibody competes with the first antibody for binding to the target antigen. See Harlow and Lane (1988) Antibodies: A Laboratory Manual ch.14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).
[0033] Fc receptors "Fc receptor" or "FcR" refers to a receptor that binds to the Fc region of an antibody. In some embodiments, the FcR is a native human FcR. In some embodiments, the FcR binds an IgG antibody (a gamma receptor) and includes receptors of the FcγRI, FcγRII, and FcγRIII subclasses, including allelic variants and alternatively spliced forms of these receptors. FcγRII receptors include FcγRIIA (an "activating receptor") and FcγRIIB (an "inhibiting receptor"), which have similar amino acid sequences that differ primarily in their cytoplasmic domains. Activating receptor FcγRIIA contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. Inhibiting receptor FcγRIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic domain. (See, e.g., Daeron, Annu. Rev. Immunol. 15:203-234 (1997).) FcRs are reviewed, e.g., in Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991); Capel et al., Immunomethods 4:25-34 (1994); and de Haas et al., J. Lab. Clin. Med 126:330-41 (1995). Other FcRs, including those identified in the future, are also encompassed by the term "FcR" herein.
[0034] The term "Fc receptor" or "FcR" also includes the neonatal receptor FcRn, which is responsible for regulating maternal IgG transfer to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)) as well as immunoglobulin homeostasis. Methods for measuring binding to FcRn are known (see, e.g., Ghetie and Ward., Immunol. Today 18(12):592-598 (1997); Ghetie et al., Nature Biotechnology, 15(7):637-640 (1997); Hinton et al., J. Biol. Chem. 279(8):6213-6216 (2004); WO2004 / 92219 (Hinton et al.)).
[0035] The in vivo binding to human FcRn and plasma half-life of human FcRn high affinity binding polypeptide can be measured, for example, in transgenic mice or transfected human cell lines expressing human FcRn, or in primates to which polypeptide with mutated Fc region is administered. WO2000 / 42072 (Presta) describes antibody mutants with increased or decreased binding to FcR. See also, for example, Shields et al. J. Biol. Chem. 9(2):6591-6604 (2001).
[0036] "Effector function" refers to a biological activity attributable to the Fc region of an antibody, which varies with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; downregulation of cell surface receptors (e.g., B cell receptor); and B cell activation.
[0037] Antibody-dependent cell-mediated cytotoxicity "Antibody-dependent cell-mediated cytotoxicity" or "ADCC" refers to a form of cytotoxicity in which the Fc region of an antibody binds to Fc receptors (FcR) present on certain cytotoxic cells (e.g., NK cells, neutrophils, and macrophages), thereby enabling these cytotoxic effector cells to specifically bind to antigen-bearing target cells and subsequently kill the target cells with cytotoxins. NK cells, the primary cells for mediating ADCC, express only FcγRIII, whereas monocytes express FcγRI, FcγRII, and FcγRIII. Expression of FcRs on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991). To assess the ADCC activity of a molecule of interest, an in vitro ADCC assay can be performed, such as those described in U.S. Patent Nos. 5,500,362 or 5,821,337 or U.S. Patent No. 6,737,056 (Presta). Useful effector cells for such assays include PBMCs and NK cells. Alternatively or additionally, the ADCC activity of a molecule of interest can be assessed in vivo in an animal model, such as the animal model disclosed in Clynes et al. PNAS (USA) 95:652-656 (1998).
[0038] Complement-dependent cytotoxicity "Complement-dependent cytotoxicity" or "CDC" refers to the lysis of target cells in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (C1q) to antibodies (of the appropriate subclass) that are bound to the corresponding antigen. To assess complement activation, a CDC assay can be performed, e.g., as described in Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996). Polypeptide variants with altered Fc region amino acid sequences (polypeptides with mutated Fc regions) and increased or decreased C1q binding ability are described, e.g., in U.S. Pat. No. 6,194,551 B1 and WO1999 / 51642. See also, e.g., Idusogie et al. J. Immunol. 164: 4178-4184 (2000).
[0039] Human effector cells "Human effector cells" refer to leukocytes that express one or more FcRs and exert effector function. In certain embodiments, the cells express at least FcγRIII and exert ADCC effector function. Examples of human leukocytes that mediate ADCC include peripheral blood mononuclear cells (PBMCs), natural killer (NK) cells, monocytes, cytotoxic T cells, and neutrophils. Effector cells can be isolated from natural sources, for example, from blood.
[0040] When the antibody-drug complex of the present disclosure is taken up into a cell, it is possible to induce cell death in the cell that has taken up the antibody by the cytotoxic substance such as a growth inhibitor or a toxic peptide linked to the complex. Therefore, it is preferable that the antibody to which a cytotoxic substance such as a growth inhibitor or a toxic peptide is linked further has internalization activity. In the present disclosure, an "antibody having internalization activity" means an antibody that is transported inside the cell (in the cytoplasm, in a vesicle, in another organelle, etc.) when bound to a target protein on the cell surface. Whether or not an antibody has internalization activity can be confirmed using a method known to those skilled in the art. For example, it can be confirmed by a method of contacting an antibody bound to a labeling substance with a cell expressing the target protein and confirming whether or not the labeling substance has been taken up into the cell, a method of contacting an antibody bound to a cytotoxic substance such as a growth inhibitor or a toxic peptide with a cell expressing the target protein and confirming whether or not cell death has been induced in the cell, etc.
[0041] An "immunoconjugate" is an antibody conjugated to one or more heterologous molecules, including but not limited to, cytotoxic agents.
[0042] As used herein, the term "cytotoxic agent" refers to a substance that inhibits or prevents the function of cells and / or causes the death or destruction of cells. Cytotoxic agents include, but are not limited to, radioisotopes (e.g., 211 At, 131 I, 125 I, 90 Y, 186 Re, 188 Re, 153 Sm, 212 Bi, 32 P, 212radioactive isotopes of Pb and Lu); chemotherapeutic agents or drugs (e.g., methotrexate, adriamycin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin, or other intercalating agents); growth inhibitors; enzymes and fragments thereof, such as nucleases; antibiotics; toxins, such as, for example, small molecule toxins or enzymatically active toxins of bacterial, fungal, plant, or animal origin (including fragments and / or variants thereof); and various anti-tumor or anti-cancer agents, as disclosed below.
[0043] "Naked antibody" refers to an antibody that is not conjugated to a heterologous moiety (e.g., a cytotoxic moiety) or a radiolabel. Naked antibodies may be present in a pharmaceutical formulation.
[0044] The term "pharmaceutical formulation" refers to a preparation in a form such that the biological activity of the active ingredients contained therein can be exerted, and which does not contain additional components that are unacceptably toxic to the subject to which the formulation is administered.
[0045] "Pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, that is non-toxic to a subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.
[0046] An "effective amount" of an agent (eg, a pharmaceutical formulation) refers to the amount, at dosages and for periods of time necessary, effective to achieve the desired therapeutic or prophylactic result.
[0047] As used herein, "treatment" (and its grammatical derivatives, such as "treat", "treating", etc.) refers to a clinical intervention intended to modify the natural course of the individual being treated, and may be performed for prophylaxis or during the course of a clinical condition. Desirable effects of treatment include, but are not limited to, prevention of disease onset or recurrence, alleviation of symptoms, attenuation of any direct or indirect pathological effects of the disease, prevention of metastasis, reduction in the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. In some embodiments, the antibodies of the present disclosure are used to delay the onset of disease or slow the progression of the disease.
[0048] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domestic animals (e.g., cows, sheep, cats, dogs, horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the individual or subject is a human.
[0049] cancer The terms "cancer" and "cancerous" refer to or describe a physiological condition in a mammal that is typically characterized by unregulated cell growth / proliferation. Examples of cancer include, but are not limited to, carcinoma, lymphoma (e.g., Hodgkin's and non-Hodgkin's lymphoma), blastoma, sarcoma, and leukemia. More specific examples of such cancer include squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous cell carcinoma of the lung, peritoneal carcinoma, hepatocellular carcinoma, gastrointestinal cancer, pancreatic cancer, glioma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine cancer, salivary gland cancer, renal cancer, liver cancer, prostate cancer, vulvar cancer, thyroid cancer, hepatocellular carcinoma, leukemia and other lymphoproliferative disorders, and various types of head and neck cancer.
[0050] tumor The term "tumor" refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues. The terms "cancer," "cancerous," "cell proliferative disorder," "proliferative disorder," and "tumor" are not mutually exclusive as used herein.
[0051] As used herein, the term "driver mutation" refers to a genetic mutation that is a direct cause of cancer onset or malignancy, and examples of important driver mutations in lung cancer and colorectal cancer include genetic mutations in ALK, RET / ROS1, KRAS, EGFR, BRAF, and ERBB2. Non-limiting examples of driver mutations include the mutations listed in Table 2.
[0052] In one embodiment, the antibody of the present disclosure is useful for at least one of treating, preventing, and diagnosing lung cancer. In a particular embodiment, the antibody of the present disclosure is useful for at least one of treating, preventing, and diagnosing lung cancer that does not have one or more selected from EGFR driver mutations, BRAF driver mutations, ERBB2 driver mutations, ALK fusion gene expression, and RET / ROS1 fusion gene expression. In another embodiment, the antibody of the present disclosure is useful for at least one of treating, preventing, and diagnosing colon cancer. In a particular embodiment, the antibody of the present disclosure is useful for at least one of treating, preventing, and diagnosing colon cancer that has a KRAS mutation.
[0053] An "isolated" antibody is one that has been separated from the components of its original environment. In some embodiments, the antibody is purified to greater than 95% or 99% purity, for example, as measured by electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reverse phase HPLC). For a review of methods for assessing antibody purity, see, for example, Flatman et al., J. Chromatogr. B 848:79-87 (2007).
[0054] An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from a component of its original environment. Isolated nucleic acid includes a nucleic acid molecule contained in a cell that normally contains the nucleic acid molecule, but where the nucleic acid molecule is present extrachromosomally or in a chromosomal location that is different from its natural chromosomal location.
[0055] An "isolated nucleic acid encoding" an antibody of the disclosure refers to one or more nucleic acid molecules encoding the antibody heavy and light chains (or fragments thereof), including nucleic acid molecules carried on a single vector or separate vectors, and including nucleic acid molecules present in one or more locations in a host cell.
[0056] As used herein, the term "vector" refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. This term includes vectors as self-replicating nucleic acid structures and vectors that are integrated into the genome of a host cell into which it is introduced. A vector can effect expression of a nucleic acid to which it is operatively linked. Such vectors are also referred to herein as "expression vectors."
[0057] The terms "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," which include the originally transformed cell and progeny derived from that cell regardless of the number of passages. The progeny may not be completely identical in nucleic acid content to the parent cell and may contain mutations. Also included herein are mutant progeny that have the same function or biological activity as that for which the original transformed cell was screened or selected.
[0058] II. Compositions and Methods In one aspect, the present disclosure is based in part on the discovery of a protein that is specifically highly expressed in cancers such as lung cancer and colon cancer. In a particular embodiment, an antibody is provided that binds to any of the target proteins XPR1, NOX1, MARVELD3 isoform 1, MARVELD3 isoform 2, SPINT2, MANSC1, SLC12A2, CDCP1, SEZ6L2, FLVCR1, SLC7A5, STEAP1, MMP14, TNFRSF21, and TMPRSS4. The antibody of the present disclosure is useful, for example, for the diagnosis or treatment of cancers such as lung cancer and colon cancer.
[0059] Exemplary Target Proteins As used herein, the term "target protein" refers to any naturally occurring target protein from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise indicated. The term encompasses "full-length" unprocessed target proteins as well as any form of target protein that results from processing in a cell. The term also encompasses naturally occurring variants of the target protein, such as splice variants and allelic variants. The amino acid sequences of exemplary target proteins of the present disclosure are shown in SEQ ID NO:1 (XPR1), SEQ ID NO:2 (NOX1), SEQ ID NO:3 (MARVELD3 isoform 1), SEQ ID NO:4 (MARVELD3 isoform 2), SEQ ID NO:5 (SPINT2), SEQ ID NO:7 (MANSC1), SEQ ID NO:8 (SLC12A2), SEQ ID NO:9 (CDCP1), SEQ ID NO:12 (SEZ6L2), SEQ ID NO:13 (FLVCR1), SEQ ID NO:14 (SLC7A5), SEQ ID NO:15 (STEAP1), SEQ ID NO:16 (MMP14), SEQ ID NO:17 (TNFRSF21), and SEQ ID NO:18 (TMPRSS4). Descriptions of exemplary target proteins of the present disclosure are provided below.
[0060] XPR1 XPR1 (xenotropic and polytropic retrovirus receptor) is a receptor that Xenotropic / polytropic mouse leukemia viruses (X / P-MLVs) infect and enter cells. XPR1 consists of 696 amino acids and contains six asparagine-type glycan-binding sites, eight transmembrane domains, and four extracellular loops (Proc Natl Acad Sci USA. 1999;96:927-932. doi: 10.1073 / pnas.96.3.927., Proc Natl Acad Sci USA. 1999;96:1385-1390. doi: 10.1073 / pnas.96.4.1385., Nat Genet. 1999;21:216-219). The original function of this protein in cells is unknown. No molecule highly homologous to XPR1 has been found in mammals, but in yeast, it has been found to share a certain degree of homology with the SYG1 protein involved in G protein-coupled fission signaling (J Biol Chem. 1995;270:25435-25444). In addition, the N-terminal hydrophilic region of XPR1 has low homology to NUC-2S in Neurospora crassa and PHO81 and PHO85 in S. cerevisiae (Trends Genet. 1995;11:209-211, Trends Biochem Sci. 1996;21:383-387, Mol Gen Genet. 1996;252:709-716). Since these molecules are involved in the control of phosphate transport, it is thought that XPR1 may be involved in signal transduction and the regulation of phosphate transport (Proc Natl Acad Sci USA. 1999;96:1385-1390. doi: 10.1073 / pnas.96.4.1385.).In addition, it has been reported that RANKL stimulation increases XPR1 mRNA expression in bone marrow cells and macrophages, suggesting that its expression is regulated by RANKL-RANK signaling (Biochem Biophys Res Commun. 2010 Aug 20;399(2):129-32). XPR1 has four extracellular loops (ECL1-4), of which ECL3 and ECL4 are particularly important as receptors for virus entry, and it is known that amino acid mutations in this region affect the susceptibility to virus infection. (J Virol. 2007 Oct; 81(19):10550-7, Retrovirology. 2009 Oct 7; 6():87, J Virol. 2010 Nov; 84(22):11970-80, J Virol. 1999 Nov; 73(11):9362-8, Retrovirology. 2005 Dec 15; 2():76, Retrovirology. 2010 Nov30; 7:101, Virology. 2016 Oct; 497: 53-58) There have been no reports to date regarding the expression or function of XPR1 in cancer. XPR1 [NP_004727.2] (SEQ ID NO: 1) consists of 696 amino acids. Based on analysis using various topology prediction software (PSORT II, UniProt, Phobius, PolyPhobius) and published literature (Proc Natl Acad Sci USA. 1999;96:927-932. doi: 10.1073 / pnas.96.3.927., Proc Natl Acad Sci USA. 1999;96:1385-1390. doi: 10.1073 / pnas.96.4.1385., Nat Genet. 1999;21:216-219), the following amino acid regions are considered to be epitopes for the TRAB antibody that recognizes XPR1 isoform 1: 244, 256-273, 257-270, 258-264, 258-268, 258-273, 260-270, 293-314, 336-343, 337-344, 338-341, 340-342, 340-344, 340-345, 368-372, 392-398, 397-401, 398-402, 420-442, 420-506, 465-479, 497-507, 498-508, 529-555, 529-570, 582-586. On the other hand, the predictions of the extracellular domain differed significantly between the two topology prediction software programs (TMHMM, Tmpred), and the following amino acid regions were considered to be epitopes for the TRAB antibody that recognizes XPR1 isoform 1: 1-234, 1-236, 293-318, 367-442, 369-473, 500-507, 529-696, and 589-696.
[0061] NOX1(NADPH OXIDASE HOMOLOG 1, NOH1, MITOGENIC OXIDASE 1, MOX1, GP91-2) NADPH oxidase is a membrane-bound enzyme complex responsible for the production of ROS, and is composed of the catalytic domain of the NOX family and several other proteins. The NOX family has seven known family members, namely, NOX 1-5, DUOX1, 2, and NOX1 is one of the family members (Physiol Rev. 2007, 87, 245-313, Cell Mol Life Sci. 2012, 69, 2327-2343). ROS generally act as cytotoxic and mutagenic substances, and are believed to be involved in the development of various chronic diseases (arteriosclerosis, hypertension, inflammation) by damaging cells (Free Radical Biol. Med., 2007, 43, 332-347, Cancer Sci., 2009, 100 (8), 1382-1388). On the other hand, increased levels of ROS have been confirmed in cancer, and ROS are thought to play an important role in the progression of cancer (Cancer. Lett., 2008, 266 (1), 37-52). In fact, increased expression of NOX / DUOX has been confirmed in many types of cancer (Anticancer Agents Med Chem. 2013, 13(3):502-14, Clinical Science, 2015, 128, 863-875). Increased expression of NOX1 has also been observed in colorectal cancer, and it has been reported that K-Ras mutations and NOX1 expression are particularly consistent (Int J Cancer. 2008,123(1):100-7). Senescence is induced by activation of downstream signals by KRas mutations, and it has been reported that ROS produced by NOX1 plays an important role in inducing senescence (Genes Cells. 2013 Jan;18 (1):32-41). NOX1 [NP_008983.2] (SEQ ID NO:2) consists of 546 amino acids. Based on analysis using various topology prediction software (PSORT II, UniProt, TMHMM, Tmpred, Phobius, PolyPhobius) and published literature (Gene. 2001, 16;269(1-2):131-40, Biochem Biophys Res Commun. 2014, 17;443(3):1060-5), the following amino acid regions are considered to be epitopes for the TRAB antibody that recognizes NOX1: 1-4, 1-11, 18-55, 28-44, 31-44, 32-46, 34-50, 70-102, 70-103, 117-176, 120-172, 122-166, 122-172, 124-168, 190-208, 191-204, 223-266, 223-267, 227-269, 228-391, 228-396, 404, 420-564.
[0062] MARVELD3(MarvelD3, Marveld3, marveld3) The intercellular adhesion surface of epithelial and endothelial cells is called tight junction (TJ), and it is composed of four proteins: claudin, occludin, trickellulin, and marvelD3. Of these, occludin, trickellulin, and marvelD3 have marvel domains, and are therefore called the TJ-associated marvel protein (TAMP) family. All of these TJ proteins have intracellular N- and C-terminal domains, and are considered to be four-loop membrane proteins with two extracellular loops (Mol. Biol. Cell. 2010, 21, 1200-1213. doi:10.1091 / mbc.E09-08-0734). There are two isoforms of marvelD3 (BMC Cell Biol. 2009, Dec 22; 10:95. doi: 10). Isoform 1 [NP_001017967.2] (SEQ ID NO:3) encodes 410 amino acids, and isoform 2 [NP_443090.4] (SEQ ID NO:4) encodes 401 amino acids. The structure prediction based on the amino acid sequence using TMPRED also predicts that marvelD3 is a protein with four transmembrane domains and two extracellular loops, with the N-terminus and C-terminus intracellular, like other TJ proteins (http: / / www.ch.embnet.org / software / TMPRED_form.html). In addition, when comparing the amino acid sequences of the two isoforms, the N-terminal 198 amino acids are the same for both, but the C-terminal sequences thereafter are completely different for both isoforms (BMC Cell Biol. 2009, Dec 22; 10:95. doi: 10). Although the expression of both isoforms 1 and 2 at the gene level has been confirmed in cultured cells and various organs, their expression at the protein level has not been analyzed (BMC Cell Biol. 2009, Dec 22; 10:95. doi: 10). Furthermore, the differences in function between the two isoforms are not known. It has been confirmed that marvelD3 colocalizes with occludin at cell junctions in both endogenous and forced expression strains (BMC Cell Biol. 2009, Dec 22; 10:95. doi: 10). Furthermore, it has been shown that marvelD3 binds homophilically in cis on the cell membrane and also binds heterophilically in cis with occludin and tricellulin, and is involved in TJ formation through interactions with other TAMPs (J Cell Sci 2013, 126: 554-564). Little is known about the role of marvelD3 in cancer, except for a report that its expression is decreased in undifferentiated pancreatic cancer cells and in pancreatic cancer cells in which EMT has been induced by snail (Exp Cell Res. 2011, Oct 1; 317(16): 2288-98). Based on the analysis using various topology prediction software (PSORT II, UniProt, TMHMM, Tmpred, Phobius, PolyPhobius) and the information in the literature (Mol. Biol. Cell. 2010, 21, 1200-1213. doi:10.1091 / mbc.E09-08-0734, BMC Cell Biol. 2009, Dec 22; 10:95. doi: 10), the following amino acid regions are considered to be the epitopes of the TRAB antibody that recognizes MARVELD3 isoform 1: 222-266, 223-269, 227-264, 227-268, 229-263, 231-265, 321-362, 322-357, 323-357, 324-357, 324-358. Similarly, the following amino acid regions are considered to be epitopes for the TRAB antibody that recognizes MARVELD3 isoform 2: 1-266, 1-270, 216-271, 222-269, 226-271, 227-268, 227-271, 248-271, 316-364, 322-360, 323-359, 324-360, 326-360, 327-360. However, some prediction software analysis results show that it has three transmembrane domains, unlike the above.
[0063] SPINT2 SPINT2 (Kunitz-type protease inhibitor 2) [NP_066925.1] (SEQ ID NO: 5) is a transmembrane protein with two extracellular Kunitz domains that inhibit serine proteases (https: / / www.ncbi.nlm.nih.gov / protein / NP_066925.1).
[0064] MANSC1 MANSC1 (MANSC domain-containing protein 1) is a protein represented by [NP_060520.2] (sequence number: 7) (https: / / www.ncbi.nlm.nih.gov / protein / NP_060520.2).
[0065] SLC12A2 SLC12A2 (solute carrier family 12 member 2) [NP_001037.1] (sequence number: 8) is a membrane protein involved in the secretion and uptake of sodium and chloride, and is said to play an important role in controlling ion balance and cell volume (https: / / www.ncbi.nlm.nih.gov / protein / NP_001037.1).
[0066] CDCP1 CDCP1 (CUB domain-containing protein 1) [NP_073753.3] (SEQ ID NO: 9) is a transmembrane protein with three extracellular domains and is known to be phosphorylated by Src family kinases (https: / / www.ncbi.nlm.nih.gov / protein / NP_073753.3).
[0067] SEZ6L2 SEZ6L2 (Seizure 6-like protein 2) [NP_963869.2] (SEQ ID NO: 12) is a protein localized in the cell membrane and is said to be possibly related to endoplasmic reticulum function in nerve cells (https: / / www.uniprot.org / uniprot / Q6UXD5; https: / / www.ncbi.nlm.nih.gov / protein / NP_963869.2).
[0068] FLVCR1 FLVCR1 (Feline leukemia virus subgroup C receptor-related protein 1) [NP_054772.1] (SEQ ID NO: 13) is a type of heme transporter and is thought to play an important role in the formation of red blood cells (https: / / www.ncbi.nlm.nih.gov / protein / NP_054772.1).
[0069] SLC7A5 SLC7A5 (Solute carrier family 7 member 5) is a protein represented by [NP_003477.4] (sequence number: 14), and is also called large neutral amino acids transporter small subunit 1 (https: / / www.ncbi.nlm.nih.gov / protein / NP_003477.4).
[0070] STEAP1 STEAP1 (Metalloreductase STEAP1) is a protein represented by [NP_036581.1] (SEQ ID NO: 15), which acts as a metalloreductase and contains Fe 3+ Fe 2+ and Cu 2+ Cu 1+ (https: / / www.uniprot.org / uniprot / Q9UHE8; https: / / www.ncbi.nlm.nih.gov / protein / NP_036581.1).
[0071] MMP14 MMP14 (Matrix metalloproteinase-14) is a protein represented by [NP_004986.1] (SEQ ID NO: 16) and has endopeptidase activity that breaks down extracellular matrix, etc. (https: / / www.ncbi.nlm.nih.gov / protein / NP_004986.1).
[0072] TNFRSF21 TNFRSF21 (Tumor necrosis factor receptor superfamily member 21) is a protein represented by [NP_055267.1] (SEQ ID NO: 17), and is thought to induce apoptosis by activating nuclear factor kappa-B and mitogen-activated protein kinase 8. It is also called Death receptor 6 (DR6) (https: / / www.ncbi.nlm.nih.gov / protein / NP_055267.1).
[0073] TMPRSS4 TMPRSS4 (Transmembrane protease serine 4) is a protein represented by [NP_063947.1] (sequence number: 18) and may be a type of serine protease (https: / / www.ncbi.nlm.nih.gov / protein / NP_063947.1).
[0074] A. Exemplary Antibodies In one aspect, the present disclosure provides an isolated antibody that binds to any of the following target proteins: XPR1, NOX1, MARVELD3 isoform 1, MARVELD3 isoform 2, SPINT2, MANSC1, SLC12A2, CDCP1, SEZ6L2, FLVCR1, SLC7A5, STEAP1, MMP14, TNFRSF21, and TMPRSS4. In certain embodiments, the antibody of the present disclosure binds to the extracellular domain of the target protein. In certain embodiments, the antibody of the present disclosure has cytotoxic activity. In certain embodiments, the antibody of the present disclosure has internalizing activity.
[0075] In one aspect, the disclosure provides antibodies capable of binding to XPR1 (XPR1-binding antibodies). In certain embodiments, the XPR1 binding antibody of the disclosure has the following amino acid sequence in the XPR1 amino acid sequence set forth in SEQ ID NO:1: Amino acids 1 to 108, 111 to 122, 159 to 171, 177 to 216, 423 to 448, 473 to 502, 660 to 670, 674 to 696, 177 to 190, 428 to 448, 660 to 670, 244, 256 to 273, 257 to 270, 258 to 264, 258 to 268, 256 to 270, 258 to 273, 260 to 270, 293 to 314, 336 to 343, 337 to 344, 338 to 341, 340 to 342, 340 The epitope is any of the sequences shown at positions 1 to 344, 343 to 344, 340 to 345, 368 to 372, 392 to 398, 397 to 401, 398 to 402, 420 to 442, 420 to 506, 465 to 479, 497 to 507, 498 to 508, 529 to 555, 529 to 570, 582 to 586, 1 to 234, 1 to 236, 293 to 318, 367 to 442, 369 to 473, 500 to 507, 529 to 696, and 589 to 696. In certain embodiments, the XPR1 binding antibody of the disclosure is any of the following (a1) to (a6): (a1) an antibody comprising HVR-H1 consisting of the amino acid sequence of SEQ ID NO: 35, HVR-H2 consisting of the amino acid sequence of SEQ ID NO: 36, HVR-H3 consisting of the amino acid sequence of SEQ ID NO: 37, HVR-L1 consisting of the amino acid sequence of SEQ ID NO: 38, HVR-L2 consisting of the amino acid sequence of SEQ ID NO: 39, and HVR-L3 consisting of the amino acid sequence of SEQ ID NO: 40; (a2) an antibody comprising the VH sequence of SEQ ID NO: 41 and the VL sequence of SEQ ID NO: 42; (a3) an antibody that binds to the same epitope in XPR1 as any one of the antibodies (a1) to (a2); (a4) an antibody that competes with the binding of any one of the antibodies (a1) to (a2) to XPR1; (a5) an antibody that inhibits the binding of any one of the antibodies (a1) to (a2) to XPR1 by 50% or more in a competitive assay; (a6) An antibody comprising a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 41 and a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 42.
[0076] In one aspect, the disclosure provides antibodies capable of binding to NOX1 (NOX1-binding antibodies). In certain embodiments, the NOX1-binding antibodies of the present disclosure are The following in the amino acid sequence shown in SEQ ID NO:2: The epitope is any of the sequences shown at amino acid positions 44 to 54, 131 to 161, 242 to 258, 1 to 4, 1 to 11, 18 to 55, 28 to 44, 31 to 44, 32 to 46, 34 to 50, 70 to 102, 70 to 103, 117 to 176, 120 to 172, 122 to 166, 122 to 172, 124 to 168, 190 to 208, 191 to 204, 223 to 266, 223 to 267, 227 to 269, 228 to 391, 228 to 396, 404, and 420 to 564. In certain embodiments, the NOX1-binding antibody of the disclosure is any of the following (b1) to (b9): (b1) an antibody comprising HVR-H1 consisting of the amino acid sequence of SEQ ID NO: 67, HVR-H2 consisting of the amino acid sequence of SEQ ID NO: 68, HVR-H3 consisting of the amino acid sequence of SEQ ID NO: 69, HVR-L1 consisting of the amino acid sequence of SEQ ID NO: 70, HVR-L2 consisting of the amino acid sequence of SEQ ID NO: 71, and HVR-L3 consisting of the amino acid sequence of SEQ ID NO: 72; (b2) an antibody comprising HVR-H1 consisting of the amino acid sequence of SEQ ID NO: 75, HVR-H2 consisting of the amino acid sequence of SEQ ID NO: 76, HVR-H3 consisting of the amino acid sequence of SEQ ID NO: 77, HVR-L1 consisting of the amino acid sequence of SEQ ID NO: 78, HVR-L2 consisting of the amino acid sequence of SEQ ID NO: 79, and HVR-L3 consisting of the amino acid sequence of SEQ ID NO: 80; (b3) an antibody comprising the VH sequence of SEQ ID NO: 73 and the VL sequence of SEQ ID NO: 74; (b4) an antibody comprising the VH sequence of SEQ ID NO: 81 and the VL sequence of SEQ ID NO: 82; (b5) an antibody that binds to the same epitope in NOX1 as any one of the antibodies (b1) to (b4); (b6) an antibody that competes with the binding of any one of the antibodies (b1) to (b4) to NOX1; (b7) an antibody that inhibits the binding of any one of the antibodies (b1) to (b4) to NOX1 by 50% or more in a competitive assay; (b8) an antibody comprising a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 73 and a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 74; (b9) An antibody comprising a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 81 and a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 82.
[0077] In one aspect, the present disclosure provides an antibody capable of binding to MARVELD3 isoform 1 (MARVELD3 isoform 1-binding antibody). In certain embodiments, the MARVELD3 isoform 1 binding antibody of the present disclosure has the following amino acid sequence as set forth in SEQ ID NO:3: The epitope is any of the sequences shown at amino acid positions 222 to 266, 223 to 269, 227 to 264, 227 to 268, 229 to 263, 231 to 265, 321 to 362, 322 to 357, 323 to 357, 324 to 357, and 324 to 358.
[0078] In one aspect, the present disclosure provides an antibody capable of binding to MARVELD3 isoform 2 (MARVELD3 isoform 2-binding antibody). In certain embodiments, the MARVELD3 isoform2 binding antibody of the present disclosure has the following amino acid sequence as set forth in SEQ ID NO:4: The epitope is any of the sequences shown at amino acid positions 101 to 111, 163 to 198, 1 to 266, 1 to 270, 216 to 271, 222 to 269, 226 to 271, 227 to 268, 227 to 271, 248 to 271, 316 to 364, 322 to 360, 323 to 359, 324 to 360, 326 to 360, and 327 to 360. In certain embodiments, a MARVELD3 isoform2 binding antibody of the disclosure is any of the following (c1) to (c9): (c1) an antibody comprising HVR-H1 consisting of the amino acid sequence of SEQ ID NO: 43, HVR-H2 consisting of the amino acid sequence of SEQ ID NO: 44, HVR-H3 consisting of the amino acid sequence of SEQ ID NO: 45, HVR-L1 consisting of the amino acid sequence of SEQ ID NO: 46, HVR-L2 consisting of the amino acid sequence of SEQ ID NO: 47, and HVR-L3 consisting of the amino acid sequence of SEQ ID NO: 48; (c2) an antibody comprising HVR-H1 consisting of the amino acid sequence of SEQ ID NO: 51, HVR-H2 consisting of the amino acid sequence of SEQ ID NO: 52, HVR-H3 consisting of the amino acid sequence of SEQ ID NO: 53, HVR-L1 consisting of the amino acid sequence of SEQ ID NO: 54, HVR-L2 consisting of the amino acid sequence of SEQ ID NO: 55, and HVR-L3 consisting of the amino acid sequence of SEQ ID NO: 56; (c3) an antibody comprising the VH sequence of SEQ ID NO: 49 and the VL sequence of SEQ ID NO: 50; (c4) an antibody comprising the VH sequence of SEQ ID NO: 57 and the VL sequence of SEQ ID NO: 58; (c5) an antibody that binds to the same epitope in MARVELD3 isoform 1 and / or MARVELD3 isoform 2 as any one of the antibodies (c1) to (c4); (c6) an antibody that competes with the binding of any one of the antibodies (c1) to (c4) to MARVELD3 isoform 1 and / or MARVELD3 isoform 2; (c7) an antibody that inhibits the binding of any one of antibodies (c1) to (c4) to MARVELD3 isoform 1 and / or MARVELD3 isoform 2 by 50% or more in a competitive assay; (c8) an antibody comprising a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 49 and a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 50; (c9) An antibody comprising a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 57 and a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 58.
[0079] In a further aspect of the disclosure, the anti-target protein antibody according to any of the above embodiments is a monoclonal antibody, including a chimeric, humanized, or human antibody. In one embodiment, the anti-target protein antibody is, for example, an Fv, Fab, Fab', scFv, diabody, or F(ab') 2In another embodiment, the antibody is a full length antibody, for example a full length IgG antibody or other antibody class or isotype as defined herein.
[0080] In further aspects, the anti-target protein antibody according to any of the above embodiments may incorporate, alone or in combination, any of the features described in items 1-7 below.
[0081] 1. Antibody affinity In certain embodiments, the antibodies provided herein have a concentration of ≦1 μM, ≦100 nM, ≦10 nM, ≦1 nM, ≦0.1 nM, ≦0.01 nM, or ≦0.001 nM (e.g., 10 -8 M or less, e.g. 10 -8 M~10 -13 M, for example 10 -9 M~10 -13 It has a dissociation constant (Kd) of 1 M.
[0082] In one embodiment, Kd is measured by radiolabeled antigen binding assay (RIA). In one embodiment, the RIA is performed using a Fab version of the antibody of interest and its antigen. For example, the solution binding affinity of the Fab for the antigen is determined by measuring the binding affinity of the Fab to the antigen at the lowest concentration ( 125I) Fab is equilibrated with labeled antigen, and then bound antigen is captured by a plate coated with anti-Fab antibody. (See, e.g., Chen et al., J. Mol. Biol. 293:865-881(1999)). To establish the measurement conditions, MICROTITER® multi-well plates (Thermo Scientific) are coated overnight with 5 μg / ml of capture anti-Fab antibody (Cappel Labs) in 50 mM sodium carbonate (pH 9.6), and then blocked with 2% (w / v) bovine serum albumin in PBS for 2-5 hours at room temperature (approximately 23°C). In non-adsorbent plates (Nunc #269620), 100 pM or 26 pM of [ 125 I]-antigen is mixed with serial dilutions of the Fab of interest (e.g., as in the evaluation of the anti-VEGF antibody, Fab-12, in Presta et al., Cancer Res. 57:4593-4599 (1997)). The Fab of interest is then incubated overnight, although the incubation can be continued for longer (e.g., about 65 hours) to ensure that equilibrium is reached. The mixture is then transferred to a capture plate for incubation at room temperature (e.g., 1 hour). The solution is then removed and the plate is washed 8 times with 0.1% polysorbate 20 (TWEEN-20®) in PBS. Once the plate has dried, 150 μl / well of scintillant (MICROSCINT-20™, Packard) is added and the plate is counted for 10 minutes in a TOPCOUNT™ gamma counter (Packard). The concentration of each Fab that gives 20% or less of maximum binding is selected for use in the competitive binding assay.
[0083] In another embodiment, Kd is measured using a BIACORE® surface plasmon resonance assay. For example, measurements using a BIACORE®-2000 or BIACORE®-3000 (BIAcore, Inc., Piscataway, NJ) are performed at 25° C. using a CM5 chip with approximately 10 response units (RU) of antigen immobilized. In one embodiment, a carboxymethylated dextran biosensor chip (CM5, BIACORE, Inc.) is activated with N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) according to the supplier's instructions. The antigen is diluted to 5 μg / ml (approximately 0.2 μM) with 10 mM sodium acetate, pH 4.8, before being injected at a flow rate of 5 μl / min to achieve approximately 10 response units (RU) of protein binding. After injection of antigen, 1 M ethanolamine is injected to block unreacted groups. For kinetic measurements, two-fold serial dilutions of Fab (0.78 nM to 500 nM) are injected in PBS containing 0.05% polysorbate 20 (TWEEN-20™) surfactant (PBST) at 25° C. with a flow rate of approximately 25 μl / min. The binding rate (k on ) and dissociation rate (k off ) is calculated by simultaneously fitting the association and dissociation sensorgrams with a simple one-to-one Langmuir binding model (BIACORE® Evaluation Software version 3.2). The equilibrium dissociation constant (Kd) is k off / k on The on-rate is calculated as a ratio of 10 to 10 by the surface plasmon resonance assay described above. See, e.g., Chen et al., J. Mol. Biol. 293:865-881 (1999). 6 M -1 s -1If the on-rate exceeds , the on-rate can be determined by using a fluorescence quenching technique to measure the increase or decrease in fluorescence emission intensity (excitation = 295 nm; emission = 340 nm, band pass 16 nm) of 20 nM anti-antigen antibody (Fab form) in PBS, pH 7.2 at 25°C in the presence of increasing concentrations of antigen as measured in a spectrometer (e.g., a stopped-flow spectrophotometer (Aviv Instruments) or an 8000 series SLM-AMINCO™ spectrophotometer (ThermoSpectronic) using a stirred cuvette).
[0084] 2. Antibody fragment In certain embodiments, the antibodies provided herein are antibody fragments. Antibody fragments include, but are not limited to, Fab, Fab', Fab'-SH, F(ab') 2 , Fv, and scFv fragments, as well as other fragments described below. For a review of certain antibody fragments, see Hudson et al. Nat. Med. 9:129-134 (2003). For a review of scFv fragments, see, e.g., Pluckthun, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., (Springer-Verlag, New York), pp.269-315 (1994); in addition, WO93 / 16185; and U.S. Patent Nos. 5,571,894 and 5,587,458. Fab and F(ab') fragments that contain salvage receptor binding epitope residues and have extended in vivo half-lives are also known. 2 For a discussion of fragments, see US Pat. No. 5,869,046.
[0085] Diabodies are antibody fragments with two antigen-binding sites, which may be bivalent or bispecific. See, e.g., EP 404,097; WO 1993 / 01161; Hudson et al., Nat. Med. 9:129-134 (2003); Hollinger et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat. Med. 9:129-134 (2003).
[0086] A single domain antibody is an antibody fragment that contains all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In certain embodiments, a single domain antibody is a human single domain antibody (Domantis, Inc., Waltham, MA; see, e.g., U.S. Patent No. 6,248,516 B1).
[0087] Antibody fragments can be produced by a variety of techniques, including, but not limited to, proteolytic digestion of whole antibodies and production by recombinant host cells (e.g., E. coli or phages), as described herein.
[0088] 3. Chimeric and humanized antibodies In certain embodiments, the antibody provided herein is a chimeric antibody. Certain chimeric antibodies are described, for example, in U.S. Patent No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984). In one example, a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a non-human primate, such as a mouse, rat, hamster, rabbit, or monkey) and a human constant region. In a further example, a chimeric antibody is a "class-switched" antibody whose class or subclass has been changed from that of the parent antibody. Chimeric antibodies also include antigen-binding fragments thereof.
[0089] In certain embodiments, the chimeric antibody is a humanized antibody. Typically, a non-human antibody is humanized to reduce immunogenicity in humans while maintaining the specificity and affinity of the parent non-human antibody. Usually, a humanized antibody comprises one or more variable domains, in which the HVRs (e.g., CDRs (or portions thereof)) are derived from a non-human antibody and the FRs (or portions thereof) are derived from human antibody sequences. The humanized antibody optionally comprises at least a portion of a human constant region. In some embodiments, some FR residues in the humanized antibody are replaced with corresponding residues from a non-human antibody (e.g., the antibody from which the HVR residues are derived), e.g., to restore or improve the specificity or affinity of the antibody.
[0090] Humanized antibodies and methods for making them are reviewed in Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008) and also see, e.g., Riechmann et al., Nature 332:323-329 (1988); Queen et al., Proc. Nat'l Acad. Sci. USA 86:10029-10033 (1989); U.S. Pat. Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri et al., Methods 36:25-34 (2005) (describing specificity determining region (SDR) grafting); Padlan, Mol. Immunol. 28:489-498 (1991) (describing resurfacing); Dall'Acqua et al., Methods 36:43-60 (2005) (describing FR shuffling); and further described in Osbourn et al., Methods 36:61-68 (2005) and Klimka et al., Br. J. Cancer, 83:252-260 (2000) (describing a "guide selection" approach for FR shuffling).
[0091] Human framework regions that may be used for humanization include, but are not limited to: framework regions selected using the "best-fit" method (see Sims et al. J. Immunol. 151:2296 (1993)); framework regions derived from consensus sequences of human antibodies of particular subgroups of light or heavy chain variable regions (see Carter et al. Proc. Natl. Acad. Sci. USA, 89:4285 (1992) and Presta et al. J. Immunol., 151:2623 (1993)); human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008)); and framework regions derived from screening of FR libraries (Baca et al., J. Biol. Chem. 272:10678-10684 (1997)). and Rosok et al., J. Biol. Chem. 271:22611-22618 (1996).
[0092] 4. Human antibodies In certain embodiments, the antibody provided herein is a human antibody. Human antibodies can be produced by various techniques known in the art. Human antibodies are reviewed in van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5: 368-74 (2001) and Lonberg, Curr. Opin. Immunol. 20:450-459 (2008).
[0093] Human antibodies may be prepared by administering an immunogen to a transgenic animal that has been engineered to produce fully human antibodies or complete antibodies with human variable regions in response to antigen challenge. Such animals typically contain all or a portion of a human immunoglobulin locus, which either replaces an endogenous immunoglobulin locus or is present extrachromosomally or randomly integrated into the animal's chromosomes. In such transgenic mice, the endogenous immunoglobulin locus is usually inactivated. For a review of methods for obtaining human antibodies from transgenic animals, see Lonberg, Nat. Biotech. 23:1117-1125 (2005). See also, for example, U.S. Patent Nos. 6,075,181 and 6,150,584, which describe XENOMOUSE™ technology; U.S. Patent No. 5,770,429, which describes HUMAB® technology; U.S. Patent No. 7,041,870, which describes KM MOUSE® technology; and U.S. Patent Application Publication No. 2007 / 0061900, which describes VELOCIMOUSE® technology. The human variable regions from complete antibodies generated by such animals may be further modified, for example, by combining with different human constant regions.
[0094] Human antibodies can also be produced by hybridoma-based methods. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described. (See, e.g., Kozbor J. Immunol., 133: 3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp.51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., J. Immunol., 147: 86 (1991).) Human antibodies generated via human B-cell hybridoma technology are also described in Li et al., Proc. Natl. Acad. Sci. USA, 103:3557-3562 (2006). Additional methods include those described, for example, in U.S. Patent No. 7,189,826 (describing the production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, Xiandai Mianyixue, 26(4):265-268 (2006) (describing human-human hybridomas). Human hybridoma technology (trioma technology) is also described in Vollmers and Brandlein, Histology and Histopathology, 20(3):927-937 (2005) and Vollmers and Brandlein, Methods and Findings in Experimental and Clinical Pharmacology, 27(3):185-91 (2005).
[0095] Human antibodies can also be generated by isolating Fv clone variable domain sequences selected from a human-derived phage display library. Such variable domain sequences can then be combined with the desired human constant domains. Techniques for selecting human antibodies from antibody libraries are described below.
[0096] 5. Library-derived Antibodies Antibodies of the present disclosure may be isolated by screening combinatorial libraries for antibodies with the desired activity or activities. For example, various methods are known in the art for generating phage display libraries and screening such libraries for antibodies with the desired binding characteristics. Such methods are reviewed in Hoogenboom et al. in Methods in Molecular Biology 178:1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, 2001) and further described in, e.g., McCafferty et al., Nature 348:552-554;Clackson et al., Nature 352: 624-628 (1991); Marks et al., J. Mol. Biol. 222: 581-597 (1992); Marks and Bradbury, in Methods in Molecular Biology 248:161-175 (Lo, ed., Human Press, Totowa, NJ, 2003); Sidhu et al., J. Mol. Biol. 338(2): 299-310 (2004); Lee et al., J. Mol. Biol. 340(5): 1073-1093 (2004); Fellouse, Proc. Natl. Acad. Sci. USA 101(34):12467-12472 (2004); and Lee et al., J. Immunol. Methods 284(1-2): 119-132(2004).
[0097] In a particular phage display method, repertoires of VH and VL genes are cloned separately by polymerase chain reaction (PCR) and randomly recombined in a phage library, which can be screened for antigen-binding phage as described in Winter et al., Ann. Rev. Immunol., 12: 433-455 (1994). Phages typically display antibody fragments, either as single-chain Fv (scFv) fragments or as Fab fragments. Libraries from immunized sources provide high affinity antibodies to the immunogen without the need to construct hybridomas. Alternatively, naive repertoires can be cloned (e.g., from humans) to provide a single source of antibodies to a wide range of non-self and self antigens without immunization, as described in Griffiths et al., EMBO J, 12: 725-734 (1993). Finally, naive libraries can be generated synthetically by cloning unrearranged V-gene segments from stem cells and using PCR primers that encode the hypervariable CDR3 regions and contain random sequences to achieve rearrangement in vitro, as described in Hoogenboom and Winter, J. Mol. Biol., 227: 381-388 (1992). Patent literature describing human antibody phage libraries includes, for example: U.S. Pat. No. 5,750,373, and U.S. Patent Application Publication Nos. 2005 / 0079574, 2005 / 0119455, 2005 / 0266000, 2007 / 0117126, 2007 / 0160598, 2007 / 0237764, 2007 / 0292936, and 2009 / 0002360.
[0098] Antibodies or antibody fragments isolated from a human antibody library are considered herein to be human antibodies or human antibody fragments.
[0099] 6. Multispecific antibodies In certain embodiments, the antibody provided herein is a multispecific antibody (e.g., a bispecific antibody). A multispecific antibody is a monoclonal antibody that has binding specificity at at least two different sites. In certain embodiments, one of the binding specificities is for the target protein and the other is for any other antigen. In certain embodiments, a bispecific antibody may bind to two different epitopes of a target protein. A bispecific antibody may be used to localize a cytotoxic agent to a cell expressing the target protein. A bispecific antibody may be prepared as a full-length antibody or as an antibody fragment.
[0100] In a particular embodiment, the multispecific antibody provided herein is a T cell redirecting antibody (TRAB). Such an antibody interacts with two or more of the target proteins of the present disclosure, i.e., a protein that is specifically and highly expressed in cancer cells and a protein that is expressed in T cells, and thus has the effect of enhancing antitumor activity by crosslinking cytotoxic T cells with cancer cells.
[0101] BiTE molecules such as blinatumomab and catumaxomab are known as bispecific antibodies that recognize proteins expressed on T cells (CD3ε and TCR) and proteins expressed on cancer cells (cancer antigens). These molecules bind to cancer antigens and CD3ε chains expressed on T cells, respectively, via two antigen-binding domains (scFv or Fab), and can bridge the T cells and cancer antigen-expressing cells. This allows such T cell redirection antibodies to induce strong cytotoxic activity against cancer antigen-expressing cells using T cells as effector cells.
[0102] In certain embodiments, the multispecific antibody of the present disclosure comprises a binding domain for a target protein of the present disclosure and a T cell receptor complex binding domain, and optionally has T cell-dependent cytotoxicity. Such a multispecific antibody of the present disclosure can redirect T cells to cells expressing the target protein of the present disclosure on the cell surface, and induce T cell-mediated cytotoxicity against the cells. In certain embodiments, the multispecific antibody of the present disclosure comprises an Fc region with reduced binding activity to Fcγ receptors, and optionally an Fc region with lower Fcγ receptor binding activity than the Fc region of IgG1, IgG2, IgG3, or IgG4. In certain embodiments, the multispecific antibody of the present disclosure comprises one binding domain for a target protein of the present disclosure. The T cell receptor complex binding domain contained in the multispecific antibody of the present disclosure is, in one embodiment, a T cell receptor binding domain having binding activity to a T cell receptor, and in another embodiment, a CD3 binding domain having binding activity to CD3. In a particular embodiment, the CD3 binding domain comprised in the multispecific antibody of the present disclosure is a domain capable of binding to the CD3 epsilon chain and optionally comprising an antibody heavy chain variable region and an antibody light chain variable region.
[0103] In certain embodiments, the CD3 binding domain comprised in a multispecific antibody of the present disclosure is any of the following (d1) to (d6): (d1) a domain comprising an antibody variable region having HVR-H1 consisting of the amino acid sequence of SEQ ID NO: 59, HVR-H2 consisting of the amino acid sequence of SEQ ID NO: 60, HVR-H3 consisting of the amino acid sequence of SEQ ID NO: 61, HVR-L1 consisting of the amino acid sequence of SEQ ID NO: 62, HVR-L2 consisting of the amino acid sequence of SEQ ID NO: 63, and HVR-L3 consisting of the amino acid sequence of SEQ ID NO: 64; (d2) a domain comprising an antibody variable region having the VH sequence of SEQ ID NO: 65 and the VL sequence of SEQ ID NO: 66; (d3) a domain comprising an antibody variable region that binds to the same epitope in CD3 as any one of the antibody variable regions (d1) to (d2); (d4) a domain comprising an antibody variable region that competes with the binding to CD3 of any one of the antibody variable regions (d1) to (d2); (d5) a domain containing an antibody variable region that inhibits the binding to CD3 of any one of the antibody variable regions (d1) to (d2) by 50% or more in a competitive assay; (d6) A domain comprising an antibody variable region having a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 65 and a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 66.
[0104] Techniques for producing multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs with different specificities (see Milstein and Cuello, Nature 305: 537 (1983), WO93 / 08829, and Traunecker et al., EMBO J. 10: 3655 (1991)), and the knob-in-hole technology (see, e.g., U.S. Pat. No. 5,731,168). Multispecific antibodies can be made by manipulating electrostatic steering effects to create Fc heterodimeric molecules (WO2009 / 089004A1); cross-linking two or more antibodies or fragments (see U.S. Pat. No. 4,676,980 and Brennan et al., Science, 229: 81 (1985)); using leucine zippers to generate antibodies with two specificities (see Kostelny et al., J. Immunol., 148(5):1547-1553 (1992)); using "diabody" technology to create bispecific antibody fragments (see Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993)); and using single-chain Fv (scFv) dimers (Gruber et al., J. Immunol., 152:5368 (1993)). (1994)); and by preparing trispecific antibodies as described, for example, in Tutt et al. J. Immunol. 147: 60 (1991).
[0105] Engineered antibodies with three or more functional antigen-binding sites are also included herein, including "octopus antibodies" (see, eg, US Patent Application Publication No. 2006 / 0025576 A1).
[0106] As used herein, the antibody or fragment also includes a "dual-acting Fab" or "DAF" that contains one antigen-binding site that binds to the target protein and another distinct antigen (see, e.g., U.S. Patent Application Publication No. 2008 / 0069820).
[0107] 7. Antibody Variants In certain embodiments, amino acid sequence variants of the antibodies provided herein are also contemplated. For example, it may be desirable to improve the binding affinity and / or other biological properties of the antibody. Amino acid sequence variants of the antibody may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody or by peptide synthesis. Such modifications include, for example, deletions from, and / or insertions into, and / or substitutions of residues in the amino acid sequence of the antibody. Any combination of deletions, insertions, and substitutions may be made to arrive at the final construct, provided that the final construct possesses the desired characteristics (e.g., antigen binding).
[0108] a) Substitution, insertion, and deletion mutants In certain embodiments, antibody variants are provided that have one or more amino acid substitutions. Target sites for substitutional mutagenesis include HVRs and FRs. Conservative substitutions are shown in Table 1 under the heading of "preferred substitutions". More substantial changes are provided in Table 1 under the heading of "exemplary substitutions" and are detailed below with reference to classes of amino acid side chains. Amino acid substitutions may be introduced into the antibody of interest, and the products may be screened for desired activity, such as, for example, retained / improved antigen binding, reduced immunogenicity, or improved ADCC or CDC.
[0109] [Table 1]
[0110] Amino acids can be divided into groups according to common side chain properties: (1) Hydrophobic: norleucine, methionine (Met), alanine (Ala), valine (Val), leucine (Leu), isoleucine (Ile); (2) neutral hydrophilic: cysteine (Cys), serine (Ser), threonine (Thr), asparagine (Asn), glutamine (Gln); (3) Acidic: aspartic acid (Asp), glutamic acid (Glu); (4) Basic: histidine (His), lysine (Lys), arginine (Arg); (5) Residues that affect chain orientation: glycine (Gly), proline (Pro); (6) Aromatic: tryptophan (Trp), tyrosine (Tyr), phenylalanine (Phe). Non-conservative substitutions refer to the exchange of a member of one of these classes for one from another class.
[0111] One type of substitutional variant involves the substitution of one or more hypervariable region residues of a parent antibody (e.g., a humanized or human antibody). Usually, the resulting variant selected for further study will have a modification (e.g., an improvement) in a particular biological property compared to the parent antibody (e.g., increased affinity, decreased immunogenicity) and / or will substantially retain a particular biological property of the parent antibody. An exemplary substitutional variant is an affinity matured antibody, which may be conveniently generated, for example, using phage display-based affinity maturation techniques (e.g., those described herein). Briefly, one or more HVR residues are mutated, and the mutated antibodies are displayed on phage and screened for a particular biological activity (e.g., binding affinity).
[0112] Modifications (e.g., substitutions) can be made in HVRs, for example, to improve the affinity of the antibody. Such modifications can be made in "hot spots" of HVRs, i.e., residues encoded by codons where mutations occur frequently during the somatic maturation process (see, e.g., Chowdhury, Methods Mol. Biol. 207:179-196 (2008)) and / or residues that contact antigens, and the resulting mutated VH or VL can be tested for binding affinity. Affinity maturation by construction and reselection from secondary libraries is described, for example, in Hoogenboom et al. in Methods in Molecular Biology 178:1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, (2001)). In some embodiments of affinity maturation, diversity is introduced into the variable genes selected for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library is then created. This library is then screened to identify any antibody variants with the desired affinity. Another method of introducing diversity involves an HVR-directed approach, where several HVR residues (e.g., 4-6 residues at a time) are randomized. HVR residues involved in antigen binding can be specifically identified, for example, using alanine scanning mutagenesis or modeling. In particular, CDR-H3 and CDR-L3 are often targeted.
[0113] In certain embodiments, substitution, insertion, or deletion may be made within one or more HVRs, as long as such modification does not substantially reduce the ability of the antibody to bind to antigen.For example, conservative modifications (e.g., conservative substitutions as provided herein) that do not substantially reduce binding affinity may be made in HVRs.Such modifications may, for example, be outside the antigen contact residues of HVRs.In certain embodiments of the above mutant VH and VL sequences, each HVR is unmodified or contains only one, two, or three amino acid substitutions.
[0114] A useful method for identifying antibody residues or regions that can be targeted for mutagenesis is that described by Cunningham and Wells (1989) Science, 244:1081-1085, called "alanine scanning mutagenesis". In this method, a residue or group of target residues (e.g., charged residues such as arginine, aspartic acid, histidine, lysine, and glutamic acid) is identified and replaced with neutral or negatively charged amino acids (e.g., alanine or polyalanine), and it is determined whether the antibody-antigen interaction is affected. Further substitutions can be introduced at amino acid positions that show functional sensitivity to this initial substitution. Alternatively or additionally, a crystal structure of the antigen-antibody complex can be analyzed to identify contact points between the antibody and the antigen. Such contact residues and neighboring residues can be targeted as replacement candidates or excluded from replacement candidates. Mutants can be screened to determine whether they contain the desired properties.
[0115] Amino acid sequence insertions include fusions ranging in length from one residue to polypeptides containing 100 or more residues at the amino and / or carboxyl termini, as well as single or multiple amino acid residue insertions within the sequence. An example of a terminal insertion includes an antibody with a methionyl residue at the N-terminus. Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody of an enzyme (e.g., for ADEPT) or a polypeptide which increases the plasma half-life of the antibody.
[0116] b) Glycosylation Mutants In certain embodiments, the antibodies provided herein have been modified to increase or decrease the extent to which the antibody is glycosylated. Adding or deleting glycosylation sites to an antibody can be conveniently accomplished by modifying the amino acid sequence to create or remove one or more glycosylation sites.
[0117] If the antibody comprises an Fc region, the carbohydrate attached thereto may be modified. Natural antibodies produced by mammalian cells typically comprise branched, biantennary oligosaccharides, which are usually attached by N-linkage to Asn297 in the CH2 domain of the Fc region. See, e.g., Wright et al. TIBTECH 15:26-32 (1997). Oligosaccharides include, for example, various carbohydrates such as mannose, N-acetylglucosamine (GlcNAc), galactose, and sialic acid, as well as fucose attached to the GlcNAc in the "stem" of the biantennary oligosaccharide structure. In some embodiments, modifications of the oligosaccharides in the antibodies of the present disclosure may be made to generate antibody variants with specific improved properties.
[0118] In one embodiment, antibody variants are provided that have carbohydrate structures that lack fucose added (directly or indirectly) to the Fc region. For example, the amount of fucose in such antibodies can be 1%-80%, 1%-65%, 5%-65% or 20%-40%. The amount of fucose is determined by calculating the average amount of fucose in the glycan at Asn297 relative to the sum of all glycostructures (e.g., complex, hybrid, and high mannose structures) added to Asn297, as measured by MALDI-TOF mass spectrometry, e.g., as described in WO2008 / 077546. Asn297 represents an asparagine residue located at about position 297 of the Fc region (EU numbering of Fc region residues). However, due to slight sequence variability between multiple antibodies, Asn297 can also be located ±3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300. Such fucosylation variants can have improved ADCC function. See, for example, U.S. Patent Application Publication Nos. 2003 / 0157108 (Presta, L.); 2004 / 0093621 (Kyowa Hakko Kogyo Co., Ltd). Examples of publications relating to "defucosylated" or "fucose-deficient" antibody variants include US2003 / 0157108; WO2000 / 61739; WO2001 / 29246; US2003 / 0115614; US2002 / 0164328; US2004 / 0093621; US2004 / 0132140; US2004 / 0110704; US2004 / 0110282; US2004 / 0109865; WO2003 / 085119; WO2003 / 084570; WO2005 / 035586; WO2005 / 035778; WO2005 / 053742; WO2002 / 031140; Okazaki et al. al. J. Mol. Biol. 336:1239-1249 (2004); Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614 (2004).Examples of cell lines capable of producing defucosylated antibodies include Lec13 CHO cells, which lack protein fucosylation (Ripka et al. Arch. Biochem. Biophys. 249:533-545 (1986); US Patent Application Publication No. US2003 / 0157108A1, Presta, L; and WO2004 / 056312A1, Adams et al., especially Example 11) and knockout cell lines, such as alpha-1,6-fucosyltransferase gene FUT8 knockout CHO cells (see, e.g., Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614 (2004); Kanda, Y. et al., Biotechnol. Bioeng., 94(4):680-688 (2006); and WO2003 / 085107).
[0119] Further provided are antibody variants having bisected oligosaccharides, for example, bisected oligosaccharides added to the Fc region of the antibody are bisected by GlcNAc. Such antibody variants may have reduced fucosylation and / or improved ADCC function. Examples of such antibody variants are described, for example, in WO2003 / 011878 (Jean-Mairet et al.); U.S. Patent No. 6,602,684 (Umana et al.); and US2005 / 0123546 (Umana et al.). Also provided are antibody variants having at least one galactose residue in the oligosaccharide added to the Fc region. Such antibody variants may have improved CDC function. Such antibody variants are described, for example, in WO1997 / 30087 (Patel et al.); WO1998 / 58964 (Raju, S.); and WO1999 / 22764 (Raju, S.).
[0120] c) Fc region mutants In certain embodiments, one or more amino acid modifications may be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant. The Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3, or IgG4 Fc region as set forth in SEQ ID NOs:6, 19, 20, 21, respectively) that contains an amino acid modification (e.g., a substitution) at one or more amino acid positions.
[0121] In certain embodiments, antibody variants with some, but not all, effector functions are also contemplated by the present disclosure, which make the antibody a desirable candidate for applications where its in vivo half-life is important, but certain effector functions (such as complement and ADCC) are unnecessary or detrimental. In vitro and / or in vivo cytotoxicity assays can be performed to confirm the reduction / lack of CDC and / or ADCC activity. For example, Fc receptor (FcR) binding assays can be performed to confirm that the antibody lacks FcγR binding (and thus likely lacks ADCC activity) while retaining FcRn binding. NK cells, the primary cells mediating ADCC, express only FcγRIII, whereas monocytes express FcγRI, FcγRII, and FcγRIII. Expression of FcR on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9:457-492 (1991). Non-limiting examples of in vitro assays to assess ADCC activity of a molecule of interest are described in U.S. Patent No. 5,500,362 (see, e.g., Hellstrom, I. et al. Proc. Nat'l Acad. Sci. USA 83:7059-7063 (1986)) and Hellstrom, I et al., Proc. Nat'l Acad. Sci. USA 82:1499-1502 (1985); U.S. Patent No. 5,821,337 (see, Bruggemann, M. et al., J. Exp. Med. 166:1351-1361 (1987)). Alternatively, non-radioactive assays may be used (see, e.g., ACT1™ non-radioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, CA); and CytoTox 96® non-radioactive cytotoxicity assays (Promega, Madison, WI)).Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells. Alternatively or additionally, ADCC activity of the molecule of interest may be assessed in vivo, e.g., in an animal model such as that described in Clynes et al. Proc. Nat'l Acad. Sci. USA 95:652-656 (1998). C1q binding assays may also be performed to confirm that the antibody is unable to bind C1q and thus lacks CDC activity. See, e.g., C1q and C3c binding ELISAs in WO2006 / 029879 and WO2005 / 100402. CDC measurements may also be performed to assess complement activation (see, e.g., Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996); Cragg, MS et al., Blood 101:1045-1052 (2003); and Cragg, MS and MJ Glennie, Blood 103:2738-2743 (2004)). In addition, FcRn binding and in vivo clearance / half-life determinations may also be performed using methods known in the art (see, e.g., Petkova, SB et al., Int'l. Immunol. 18(12):1759-1769 (2006)).
[0122] Antibodies with reduced effector function include those with one or more substitutions at Fc region residues 238, 265, 269, 270, 297, 327, and 329 (U.S. Patent No. 6,737,056). Such Fc variants include Fc variants with substitutions at two or more amino acid positions 265, 269, 270, 297, and 327, including the so-called "DANA" Fc variant with substitutions of residues 265 and 297 to alanine (U.S. Patent No. 7,332,581).
[0123] Certain antibody variants with increased or decreased binding to FcRs have been described (see U.S. Pat. No. 6,737,056; WO2004 / 056312, and Shields et al., J. Biol. Chem. 9(2): 6591-6604 (2001)).
[0124] In certain embodiments, the antibody variant comprises an Fc region with one or more amino acid substitutions that improve ADCC (e.g., substitutions at positions 298, 333, and / or 334 (residues in EU numbering) of the Fc region).
[0125] In some embodiments, modifications are made in the Fc region that result in altered (i.e., either increased or decreased) C1q binding and / or complement dependent cytotoxicity (CDC), e.g., as described in U.S. Pat. No. 6,194,551, WO99 / 51642, and Idusogie et al. J. Immunol. 164: 4178-4184 (2000).
[0126] Antibodies with increased half-lives and increased binding to the neonatal Fc receptor (FcRn, responsible for the transfer of maternal IgGs to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)) have been described in U.S. Patent Application Publication No. 2005 / 0014934 A1 (Hinton et al.). These antibodies comprise an Fc region with one or more substitutions therein that increase binding of the Fc region to FcRn. Such Fc variants include those with substitutions at one or more of Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424, or 434 (e.g., substitution at Fc region residue 434 (U.S. Patent No. 7,371,826)).
[0127] For other examples of Fc region variants, see also Duncan & Winter, Nature 322:738-40 (1988); U.S. Patent No. 5,648,260; U.S. Patent No. 5,624,821; and WO 94 / 29351.
[0128] d) Cysteine Engineered Antibody Variants In certain embodiments, it may be desirable to create cysteine engineered antibodies (e.g., "thioMAbs") in which one or more residues of an antibody are substituted with a cysteine residue. In certain embodiments, the substituted residues occur at accessible sites of the antibody. By substituting those residues with cysteine, reactive thiol groups are placed at accessible sites of the antibody, which may be used to conjugate the antibody to other moieties (such as drug moieties or linker-drug moieties) to create immunoconjugates as further detailed herein. In certain embodiments, any one or more of the following residues may be substituted with a cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and S400 (EU numbering) of the heavy chain Fc region. Cysteine engineered antibodies may be generated, for example, as described in U.S. Pat. No. 7,521,541.
[0129] e) Antibody derivative In certain embodiments, the antibodies provided herein may be further modified to include additional non-protein moieties that are known in the art and readily available. Moieties suitable for derivatization of antibodies include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone, poly 1,3 dioxolane, poly 1,3,6, trioxane, ethylene / maleic anhydride copolymers, polyamino acids (either homopolymers or random copolymers), and dextran or poly(n-vinylpyrrolidone) polyethylene glycol, polypropylene glycol homopolymer, polypropylene oxide / ethylene oxide copolymer, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may be advantageous in manufacturing due to its stability in water. The polymer may be of any molecular weight and may be branched or unbranched. The number of polymers attached to an antibody can vary, and if more than one polymer is attached, they can be the same molecule or different molecules. In general, the number and / or type of polymers used for derivatization can be determined based on considerations such as, but not limited to, the particular property or function of the antibody to be improved, whether the antibody derivative will be used in therapy under defined conditions, etc.
[0130] In another embodiment, a conjugate is provided between an antibody and a non-protein moiety that can be selectively heated by exposure to radiation. In one embodiment, the non-protein moiety is a carbon nanotube (Kam et al., Proc. Natl. Acad. Sci. USA 102: 11600-11605 (2005)). The radiation can be of any wavelength, including but not limited to wavelengths that heat the non-protein moiety to a temperature that is not harmful to normal cells but that kills cells in close proximity to the antibody-non-protein moiety.
[0131] B. Antibody Production Methods Methods for producing antibodies having the desired binding activity are known to those skilled in the art, and the antibodies can be obtained as polyclonal or monoclonal antibodies. As the antibody of the present disclosure, a monoclonal antibody derived from a mammal can be preferably produced. The monoclonal antibody derived from a mammal includes those produced by hybridomas and those produced by host cells transformed with an expression vector containing an antibody gene by genetic engineering techniques.
[0132] The mammalian animal to be immunized to obtain the antibody is not limited to a specific animal, but is preferably selected in consideration of compatibility with the parent cell used in cell fusion to prepare the hybridoma. In general, rodents such as mice, rats, hamsters, rabbits, monkeys, etc. are preferably used.
[0133] The above-mentioned animals are immunized with the sensitizing antigen according to a known method. For example, as a general method, the immunization is carried out by administering the sensitizing antigen to the mammal by intraperitoneal or subcutaneous injection. Specifically, the sensitizing antigen diluted at an appropriate dilution ratio with PBS (Phosphate-Buffered Saline) or physiological saline, etc., is mixed with a conventional adjuvant, such as Freund's complete adjuvant, if desired, and emulsified, and then the sensitizing antigen is administered to the mammal several times every 4 to 21 days. In addition, a suitable carrier may be used during immunization with the sensitizing antigen. In particular, when a partial peptide with a small molecular weight is used as the sensitizing antigen, it may be desirable to immunize with the sensitizing antigen peptide bound to a carrier protein such as albumin or keyhole limpet hemocyanin.
[0134] Hybridomas producing the desired antibodies can also be prepared using DNA immunization as follows. DNA immunization is an immunization method in which a vector DNA constructed in such a manner that a gene encoding an antigen protein can be expressed in the immunized animal is administered to the immunized animal, and a sensitizing antigen is expressed in the body of the immunized animal, thereby providing immune stimulation. Compared to general immunization methods in which a protein antigen is administered to an immunized animal, DNA immunization is expected to have the following advantages: -Maintains the structure of membrane proteins and can provide immune stimulation -No need to purify the immunogen
[0135] In order to obtain the monoclonal antibody of the present disclosure by DNA immunization, first, DNA expressing an antigen protein is administered to an animal to be immunized. The DNA encoding the antigen protein can be synthesized by a known method such as PCR. The obtained DNA is inserted into an appropriate expression vector and administered to the animal to be immunized. As the expression vector, for example, a commercially available expression vector such as pcDNA3.1 can be suitably used. As a method for administering a vector to a living body, a commonly used method can be used. For example, DNA immunization is performed by introducing gold particles to which an expression vector is adsorbed into the cells of an individual animal to be immunized using a gene gun.
[0136] After the mammal is immunized in this manner and an increase in the antibody titer that binds to the antigen in the serum is confirmed, immune cells are collected from the mammal and subjected to cell fusion. As the preferred immune cells, spleen cells can be particularly used.
[0137] Mammalian myeloma cells are used as the cells to be fused with the immune cells. The myeloma cells are preferably provided with an appropriate selection marker for screening. The selection marker refers to a trait that allows (or does not allow) a cell to survive under specific culture conditions. Known selection markers include hypoxanthine-guanine-phosphoribosyltransferase deficiency (hereinafter abbreviated as HGPRT deficiency) and thymidine kinase deficiency (hereinafter abbreviated as TK deficiency). Cells with HGPRT or TK deficiency have hypoxanthine-aminopterin-thymidine sensitivity (hereinafter abbreviated as HAT sensitivity). HAT-sensitive cells cannot synthesize DNA in HAT selection medium and die, but when fused with normal cells, they can continue to synthesize DNA by utilizing the salvage circuit of normal cells, and therefore grow even in HAT selection medium.
[0138] HGPRT-deficient or TK-deficient cells can be selected on media containing 6-thioguanine, 8-azaguanine (hereafter abbreviated as 8AG), or 5'-bromodeoxyuridine, respectively. Normal cells that incorporate these pyrimidine analogs into their DNA die. On the other hand, cells lacking these enzymes that cannot incorporate these pyrimidine analogs can survive in the selective medium. Another selection marker called G418 resistance confers resistance to 2-deoxystreptamine antibiotics (gentamicin analogs) via the neomycin resistance gene. Various myeloma cells suitable for cell fusion are known.
[0139] Examples of such myeloma cells include P3 (P3x63Ag8.653) (J. Immunol. (1979) 123 (4), 1548-1550), P3x63Ag8U.1 (Current Topics in Microbiology and Immunology (1978) 81, 1-7), NS-1 (C. Eur. J. Immunol. (1976) 6 (7), 511-519), MPC-11 (Cell (1976) 8 (3), 405-415), SP2 / 0 (Nature (1978) 276 (5685), 269-270), FO (J. Immunol. Methods (1980) 35 (1-2), 1-21), and S194 / 5.XX0.BU.1 (J. Exp. Med. (1978) 148 (1), 313-323), R210 (Nature (1979) 277 (5692), 131-133), etc. can be suitably used.
[0140] Basically, cell fusion between the immune cells and myeloma cells is carried out according to known methods, for example, the method of Kohler and Milstein et al. (Methods Enzymol. (1981) 73, 3-46).
[0141] More specifically, the cell fusion can be carried out in a normal nutrient culture medium in the presence of a cell fusion promoter, such as polyethylene glycol (PEG) or Sendai virus (HVJ), and if desired, an auxiliary agent such as dimethyl sulfoxide can be added to enhance the fusion efficiency.
[0142] The ratio of immune cells to myeloma cells may be set arbitrarily. For example, it is preferable to use 1 to 10 times more immune cells than myeloma cells. As the culture medium used for the cell fusion, for example, RPMI1640 culture medium suitable for the growth of the myeloma cell line, MEM culture medium, or other usual culture medium used for this type of cell culture may be used, and serum supplements such as fetal calf serum (FCS) may be suitably added.
[0143] For cell fusion, a predetermined amount of the immune cells and myeloma cells are thoroughly mixed in the culture medium, and a PEG solution (e.g., average molecular weight of about 1000 to 6000) pre-warmed to about 37°C is added, usually at a concentration of 30 to 60% (w / v). The mixture is gently mixed to form the desired fused cells (hybridomas). Next, the appropriate culture medium listed above is successively added, and the procedure of centrifuging and removing the supernatant is repeated to remove cell fusion agents and the like that are undesirable for hybridoma growth.
[0144] The hybridomas thus obtained can be selected by culturing them in a conventional selection medium, such as HAT medium (a medium containing hypoxanthine, aminopterin and thymidine). The culture can be continued using the above HAT medium for a sufficient time (usually several days to several weeks) for cells other than the desired hybridoma (non-fused cells) to die. Then, screening and single cloning of hybridomas producing the desired antibody are performed by a conventional limiting dilution method.
[0145] The hybridomas thus obtained can be selected by using a selection medium according to the selection marker possessed by the myeloma used in the cell fusion. For example, cells lacking HGPRT or TK can be selected by culturing in HAT culture medium (a culture medium containing hypoxanthine, aminopterin and thymidine). That is, when HAT-sensitive myeloma cells are used in the cell fusion, cells that have successfully fused with normal cells can selectively grow in the HAT culture medium. The culture is continued using the above-mentioned HAT culture medium for a sufficient time for cells other than the desired hybridoma (non-fused cells) to die. Specifically, the desired hybridoma can generally be selected by culturing for several days to several weeks. Next, screening and single cloning of hybridomas that produce the desired antibody can be performed by the usual limiting dilution method.
[0146] Screening and single cloning of the desired antibody can be suitably carried out by a screening method based on a known antigen-antibody reaction. The desired antibody can be screened, for example, by FACS (fluorescence activated cell sorting). FACS is a system that allows the binding of the antibody to the cell surface to be measured by analyzing cells contacted with a fluorescent antibody with laser light and measuring the fluorescence emitted by each cell.
[0147] In order to screen hybridomas that produce the monoclonal antibody of the present disclosure by FACS, first prepare cells that express the antigen to which the produced antibody binds. A preferred cell for screening is a mammalian cell that is forced to express the antigen. By using non-transformed mammalian cells used as host cells as a control, the binding activity of the antibody to the antigen on the cell surface can be selectively detected. That is, by selecting hybridomas that produce antibodies that do not bind to host cells but bind to cells that are forced to express the antigen, hybridomas that produce the desired monoclonal antibody can be obtained.
[0148] Alternatively, cells expressing the target antigen can be immobilized, and the binding activity of the antibody to the antigen-expressing cells can be evaluated based on the principle of ELISA. For example, antigen-expressing cells are immobilized in the wells of an ELISA plate. The culture supernatant of the hybridoma is contacted with the immobilized cells in the wells, and the antibody that binds to the immobilized cells is detected. If the monoclonal antibody is derived from a mouse, the antibody that binds to the cells can be detected by an anti-mouse immunoglobulin antibody. Hybridomas that produce the desired antibody that has the binding ability to the antigen and are selected by these screenings can be cloned by limiting dilution or the like. The hybridomas producing the monoclonal antibodies thus prepared can be subcultured in a normal culture medium, and can be stored for a long period of time in liquid nitrogen.
[0149] The hybridoma is cultured according to a conventional method, and the desired monoclonal antibody can be obtained from the culture supernatant. Alternatively, the hybridoma can be administered to a compatible mammal to proliferate, and the monoclonal antibody can be obtained from the ascites. The former method is suitable for obtaining highly pure antibodies.
[0150] Antibodies encoded by antibody genes cloned from antibody-producing cells such as hybridomas can also be suitably used. The cloned antibody gene is incorporated into an appropriate vector and introduced into a host, whereby the antibody encoded by the gene is expressed. Methods for isolating antibody genes, introducing them into vectors, and transforming host cells have already been established, for example, by Vandamme et al. (Eur. J. Biochem. (1990) 192 (3), 767-775). Methods for producing recombinant antibodies are also known, as described below.
[0151] To obtain cDNA encoding the variable region (V region) of an antibody, total RNA is usually extracted from the hybridoma first. The following methods can be used to extract mRNA from cells. -Guanidine ultracentrifugation (Biochemistry (1979) 18 (24), 5294-5299) -AGPC method (Anal. Biochem. (1987) 162 (1), 156-159)
[0152] The extracted mRNA can be purified using, for example, mRNA Purification Kit (GE Healthcare Biosciences). Alternatively, kits for directly extracting total mRNA from cells, such as QuickPrep mRNA Purification Kit (GE Healthcare Biosciences), are also commercially available. Using such a kit, mRNA can be obtained from a hybridoma. cDNA encoding an antibody V region can be synthesized from the obtained mRNA using reverse transcriptase. cDNA can be synthesized using AMV Reverse Transcriptase First-strand cDNA Synthesis Kit (Seikagaku Kogyo Co., Ltd.) or the like. In addition, for the synthesis and amplification of cDNA, SMART RACE cDNA Amplification Kit (Clontech) and the 5'-RACE method using PCR (Proc. Natl. Acad. Sci. USA (1988) 85 (23), 8998-9002, Nucleic Acids Res. (1989) 17 (8), 2919-2932) can be appropriately used. Furthermore, during the process of synthesizing such cDNA, appropriate restriction enzyme sites (described below) can be introduced at both ends of the cDNA.
[0153] The desired cDNA fragment is purified from the obtained PCR product and then ligated to a vector DNA. The recombinant vector is thus prepared, introduced into E. coli or the like, and colonies are selected, after which the desired recombinant vector can be prepared from the E. coli that formed the colonies. Then, whether or not the recombinant vector has the base sequence of the desired cDNA is confirmed by a known method, for example, the dideoxynucleotide chain termination method.
[0154] To obtain genes encoding variable regions, it is easy to use the 5'-RACE method using primers for amplifying variable region genes. First, cDNA is synthesized using RNA extracted from hybridoma cells as a template to obtain a 5'-RACE cDNA library. A commercially available kit such as the SMART RACE cDNA Amplification Kit can be used to synthesize the 5'-RACE cDNA library.
[0155] The resulting 5'-RACE cDNA library is used as a template to amplify antibody genes by PCR. Primers for amplifying mouse antibody genes can be designed based on known antibody gene sequences. These primers have different base sequences for each immunoglobulin subclass. Therefore, it is desirable to determine the subclass in advance using a commercially available kit such as the Iso Strip Mouse Monoclonal Antibody Isotyping Kit (Roche Diagnostics).
[0156] Specifically, for example, when the objective is to obtain a gene encoding mouse IgG, primers capable of amplifying genes encoding γ1, γ2a, γ2b, and γ3 as heavy chains and κ and λ chains as light chains can be used. To amplify the variable region genes of IgG, a primer that anneals to a portion corresponding to the constant region close to the variable region is generally used as the 3' primer. On the other hand, a primer included in the 5' RACE cDNA library construction kit is used as the 5' primer.
[0157] Using the PCR products thus amplified, immunoglobulins consisting of a combination of heavy and light chains can be reconstituted. The desired antibodies can be screened using the antigen-binding activity of the reconstituted immunoglobulins as an index. For example, screening can be performed as follows: (1) contacting an antibody comprising a V region encoded by a cDNA obtained from a hybridoma with a cell expressing a desired antigen; (2) detecting binding of the antigen-expressing cells to the antibody; and (3) selecting an antibody that binds to the antigen-expressing cells.
[0158] The method of detecting the binding between an antibody and the antigen-expressing cell is known. Specifically, the binding between an antibody and the antigen-expressing cell can be detected by the above-mentioned technique such as FACS. A fixed specimen of the antigen-expressing cell can be appropriately used to evaluate the binding activity of the antibody.
[0159] As a method for screening antibodies using binding activity as an index, a panning method using a phage vector is also preferably used. When antibody genes are obtained as a library of heavy and light chain subclasses from a polyclonal antibody-expressing cell group, a screening method using a phage vector is advantageous. Genes encoding the variable regions of the heavy and light chains can be linked with an appropriate linker sequence to form a single chain Fv (scFv). By inserting a gene encoding an scFv into a phage vector, a phage expressing scFv on its surface can be obtained. After contacting this phage with a desired antigen, the phage bound to the antigen can be recovered to recover DNA encoding an scFv having the desired binding activity. By repeating this operation as necessary, scFv having the desired binding activity can be concentrated.
[0160] After obtaining cDNA encoding the V region of the target antibody, the cDNA is digested with a restriction enzyme that recognizes the restriction enzyme sites inserted at both ends of the cDNA. A preferred restriction enzyme recognizes and digests a base sequence that appears infrequently in the base sequence constituting the antibody gene. Furthermore, in order to insert one copy of the digested fragment into a vector in the correct direction, it is preferable to insert a restriction enzyme that gives a sticky end. An antibody expression vector can be obtained by inserting the cDNA encoding the V region of the antibody digested as described above into an appropriate expression vector. At this time, if a gene encoding an antibody constant region (C region) and a gene encoding the V region are fused in frame, a chimeric antibody can be obtained. Here, a chimeric antibody refers to an antibody whose constant region and variable region are derived from different sources. Therefore, in addition to heterogeneous chimeric antibodies such as mouse-human, human-human allogeneic chimeric antibodies are also included in the chimeric antibodies of the present disclosure. A chimeric antibody expression vector can be constructed by inserting the V region gene into an expression vector that already has a constant region. Specifically, for example, a restriction enzyme recognition sequence for a restriction enzyme that digests the V region gene can be appropriately positioned on the 5' side of an expression vector carrying DNA encoding a desired antibody constant region (C region). A chimeric antibody expression vector is constructed by fusing the two genes digested with the same combination of restriction enzymes in frame.
[0161] To produce a monoclonal antibody, an antibody gene is incorporated into an expression vector so that it is expressed under the control of an expression control region. Expression control regions for expressing an antibody include, for example, enhancers and promoters. In addition, a suitable signal sequence can be added to the amino terminus so that the expressed antibody is secreted outside the cell. The signal sequence is cleaved from the carboxyl terminal portion of the expressed polypeptide, and the antibody can be secreted outside the cell. Then, a suitable host cell is transformed with this expression vector to obtain a recombinant cell expressing DNA encoding the antibody.
[0162] For the expression of antibody genes, DNAs encoding the antibody heavy chain (H chain) and light chain (L chain) are incorporated into separate expression vectors. An antibody molecule comprising an H chain and an L chain can be expressed by simultaneously transforming (co-transfecting) the same host cell with vectors incorporating the H chain and the L chain. Alternatively, a host cell can be transformed by incorporating DNAs encoding the H chain and the L chain into a single expression vector (see International Publication WO 94 / 11523).
[0163] Many combinations of host cells and expression vectors are known for producing antibodies by introducing isolated antibody genes into a suitable host. Any of these expression systems can be applied to isolate the above-mentioned target protein-binding domain or T cell receptor complex-binding domain of the present disclosure.
[0164] When eukaryotic cells are used as host cells, animal cells, plant cells, or fungal cells can be used as appropriate. Specifically, examples of animal cells include the following cells: (1) Mammalian cells: CHO, COS, myeloma, BHK (baby hamster kidney), Hela, Vero, etc. (2) Amphibian cells: Xenopus oocytes, etc. (3) Insect cells: sf9, sf21, Tn5, etc.
[0165] Alternatively, an antibody gene expression system using plant cells derived from the genus Nicotiana, such as Nicotiana tabacum, is known. For transformation of plant cells, callus cultured cells can be appropriately used.
[0166] Furthermore, the following fungal cells can be used: - Yeast: Saccharomyces genus such as Saccharomyces cerevisiae, Pichia genus such as Pichia pastoris - Filamentous fungi: Aspergillus genus, such as Aspergillus niger
[0167] In addition, antibody gene expression systems using prokaryotic cells are also known. For example, when bacterial cells are used, bacterial cells such as Escherichia coli (E. coli) and Bacillus subtilis can be appropriately used. An expression vector containing the target antibody gene is introduced into these cells by transformation. The transformed cells are cultured in vitro, and the desired antibody can be obtained from the culture of the transformed cells.
[0168] In addition to the above-mentioned host cells, transgenic animals can also be used to produce recombinant antibodies. That is, the antibody can be obtained from an animal into which a gene encoding the desired antibody has been introduced. For example, an antibody gene can be constructed as a fusion gene by in-frame insertion into a gene encoding a protein that is produced specifically in milk. For example, goat β-casein can be used as a protein secreted into milk. A DNA fragment containing the fusion gene into which the antibody gene has been inserted is injected into a goat embryo, and the injected embryo is introduced into a female goat. The desired antibody can be obtained as a fusion protein with a milk protein from the milk produced by the transgenic goat (or its offspring) born from the goat that received the embryo. Also, a hormone can be administered to the transgenic goat to increase the amount of milk containing the desired antibody produced by the transgenic goat (Bio / Technology (1994), 12 (7), 699-702).
[0169] When the antigen-binding molecules described herein are administered to humans, for example, when a domain containing an antibody variable region is used as the various binding domains in the molecule, an antigen-binding domain derived from a genetically engineered antibody that has been artificially modified for the purpose of reducing heterologous antigenicity against humans, etc., may be appropriately used. Genetically engineered antibodies include, for example, humanized antibodies. These modified antibodies are appropriately produced using known methods.
[0170] The variable region of an antibody used to prepare various binding domains in the antigen-binding molecules described herein is usually composed of three complementarity-determining regions (CDRs) sandwiched between four framework regions (FRs). CDRs are regions that essentially determine the binding specificity of an antibody. The amino acid sequences of CDRs are highly diverse. On the other hand, the amino acid sequences constituting FRs often show high identity even between antibodies with different binding specificities. Therefore, it is generally believed that the binding specificity of a certain antibody can be transplanted to another antibody by transplanting CDRs.
[0171] A humanized antibody is also called a reshaped human antibody. Specifically, humanized antibodies in which the CDR of an animal other than human, for example, a mouse antibody, is transplanted to a human antibody are known. General gene recombination techniques for obtaining humanized antibodies are also known. Specifically, overlap extension PCR is known as a method for transplanting the CDR of a mouse antibody to a human FR. In overlap extension PCR, a base sequence encoding the CDR of the mouse antibody to be transplanted is added to a primer for synthesizing the FR of a human antibody. Primers are prepared for each of the four FRs. In general, in transplanting mouse CDRs to human FRs, it is considered to be advantageous to select a human FR that is highly identical to the mouse FR in terms of maintaining the function of the CDR. That is, it is generally preferable to use a human FR that is composed of an amino acid sequence that is highly identical to the amino acid sequence of the FR adjacent to the mouse CDR to be transplanted.
[0172] The base sequences to be linked are designed to be connected in frame with each other. Human FRs are synthesized individually using each primer. As a result, products are obtained in which DNA encoding mouse CDRs is added to each FR. The base sequences encoding mouse CDRs of each product are designed to overlap with each other. Next, the overlapping CDR portions of the products synthesized using the human antibody gene as a template are annealed to each other to perform a complementary strand synthesis reaction. Through this reaction, the human FRs are linked via the mouse CDR sequences.
[0173] Finally, the V region gene in which three CDRs and four FRs are linked is amplified in its entirety by primers that anneal to the 5' and 3' ends and have appropriate restriction enzyme recognition sequences added thereto. A human antibody expression vector can be prepared by inserting the DNA obtained as described above and a DNA encoding a human antibody C region into an expression vector so as to fuse in frame. After introducing the integration vector into a host to establish a recombinant cell, the recombinant cell is cultured and the DNA encoding the humanized antibody is expressed, whereby the humanized antibody is produced in the culture of the cultured cells (see European Patent Publication EP 239400 and International Publication WO1996 / 002576).
[0174] By qualitatively or quantitatively measuring and evaluating the antigen-binding activity of the humanized antibody prepared as described above, it is possible to suitably select the FR of a human antibody in which the CDR forms a good antigen-binding site when linked via the CDR. If necessary, amino acid residues in the FR can be substituted so that the CDR of the reshaped human antibody forms a suitable antigen-binding site. For example, a mutation in the amino acid sequence can be introduced into the FR by applying the PCR method used for transplanting mouse CDRs into human FRs. Specifically, a partial mutation in the base sequence can be introduced into a primer annealing to the FR. A mutation in the base sequence is introduced into the FR synthesized by such a primer. A mutant FR sequence having desired properties can be selected by measuring and evaluating the antigen-binding activity of a mutant antibody with amino acid substitutions by the above method (Sato, K. et al., Cancer Res, 1993, 53, 851-856).
[0175] Furthermore, transgenic animals carrying the entire repertoire of human antibody genes (see International Publications WO1993 / 012227, WO1992 / 003918, WO1994 / 002602, WO1994 / 025585, WO1996 / 034096, and WO1996 / 033735) can be used as immunized animals to obtain desired human antibodies by DNA immunization.
[0176] Furthermore, a technique for obtaining a human antibody by panning using a human antibody library is also known. For example, the V region of a human antibody is expressed on the surface of a phage as a single chain antibody (scFv) by phage display. A phage expressing an scFv that binds to an antigen can be selected. By analyzing the gene of the selected phage, the DNA sequence encoding the V region of a human antibody that binds to an antigen can be determined. After determining the DNA sequence of the scFv that binds to an antigen, the V region sequence can be fused in frame with the sequence of the C region of a desired human antibody and then inserted into an appropriate expression vector to prepare an expression vector. The expression vector is introduced into a suitable expression cell as listed above, and the gene encoding the human antibody is expressed to obtain the human antibody. These methods are already known (see International Publications WO1992 / 001047, WO1992 / 020791, WO1993 / 006213, WO1993 / 011236, WO1993 / 019172, WO1995 / 001438, and WO1995 / 015388).
[0177] In addition to the phage display method, techniques for obtaining human antibodies by panning using a human antibody library include techniques using a cell-free translation system, techniques for displaying antigen-binding molecules on the surface of cells or viruses, and techniques using emulsions. For example, techniques using a cell-free translation system include the ribosome display method, which forms a complex between mRNA and the translated protein via ribosomes by removing a stop codon, the cDNA display method, which covalently binds a gene sequence to a translated protein using a compound such as puromycin, the mRNA display method, and the CIS display method, which forms a complex between a gene and a translated protein using a nucleic acid-binding protein. In addition to the phage display method, techniques for displaying antigen-binding molecules on the surface of cells or viruses include the E. coli display method, the Gram-positive bacteria display method, the yeast display method, the mammalian cell display method, and the virus display method. Techniques using emulsions include the in vitro virus display method, which involves encapsulating genes and translation-related molecules in an emulsion. These methods are already known (Nat Biotechnol. 2000 Dec;18(12):1287-92, Nucleic Acids Res. 2006;34(19):e127, Proc Natl Acad Sci US A. 2004 Mar 2;101(9):2806-10, Proc Natl Acad Sci US A. 2004 Jun 22;101(25):9193-8, Protein Eng Des Sel. 2008 Apr;21(4):247-55, Proc Natl Acad Sci US A. 2000 Sep 26;97(20):10701-5, MAbs. 2010 Sep-Oct;2(5):508-18, Methods Mol Biol. 2012;911:183-98).
[0178] C. Assays The anti-target protein antibodies provided herein may be identified, screened, or characterized for their physical / chemical properties and / or biological activity by a variety of assays known in the art.
[0179] 1. Binding and other assays In one aspect, the antibodies of the disclosure are tested for their antigen binding activity by known methods, such as ELISA, Western blot, and the like.
[0180] 2.Activity measurement method In one aspect, a method for identifying the antibody of the present disclosure having biological activity is provided.Biological activity may include, for example, cytotoxic activity (ADCC activity, CDC activity, etc.) and internalization activity.Antibodies having such biological activity in vivo and / or in vitro are also provided.
[0181] D. Immunoconjugates The present disclosure also provides immunoconjugates comprising an antibody of the present disclosure conjugated to one or more cytotoxic agents (e.g., a chemotherapeutic agent or drug, a growth inhibitory agent, a toxin (e.g., a protein toxin of bacterial, fungal, plant or animal origin, an enzymatically active toxin, or fragments thereof), or a radioactive isotope).
[0182] In one embodiment, the immunoconjugate is an antibody-drug conjugate (ADC) in which an antibody is conjugated to one or more drugs, including but not limited to: maytansinoids (see U.S. Pat. Nos. 5,208,020, 5,416,064, and European Patent No. 0,425,235 B1); auristatins, such as the monomethylauristatin drug moieties DE and DF (MMAE and MMAF) (see U.S. Pat. Nos. 5,635,483, 5,780,588, and 7,498,298); dolastatins; calicheamicin or a derivative thereof (see U.S. Pat. Nos. 5,712,374, 5,714,586, 5,739,116, 5,767,285, 5,770,701, 5,770,710, 5,773,001, and 5,877,296; Hinman et al., Cancer Res. 53:3336-3342; (1993); and see Lode et al., Cancer Res. 58:2925-2928 (1998)); anthracyclines such as daunomycin or doxorubicin (Kratz et al., Current Med. Chem. 13:477-523 (2006); Jeffrey et al., Bioorganic & Med. Chem. Letters 16:358-362 (2006); Torgov et al., Bioconj. Chem. 16:717-721 (2005); Nagy et al., Proc. Natl. Acad. Sci. USA 97:829-834 (2000); Dubowchik et al., Bioorg. & Med. Chem. Letters 12:1529-1532 (2002); King et al., J. Med. Chem. 45:4336-4343 (2002); and U.S. Patent No. 6,630,579); methotrexate; vindesine; taxanes such as docetaxel, paclitaxel, larotaxel, tesetaxel, and ortataxel; trichothecenes; and CC1065.
[0183] In another embodiment, the immunoconjugate comprises an antibody as described herein conjugated to an enzymatically active toxin or fragment thereof, including, but not limited to, diphtheria A chain, nonbinding active fragment of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii protein, dianthin protein, Phytolacca americana protein (PAPI, PAPII and PAP-S), momordica charantia inhibitor, curcin, crotin, saponaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the trichothecenes.
[0184] In another embodiment, the immunoconjugate comprises an antibody as described herein conjugated to a radioactive atom to form a radioconjugate. A variety of radioisotopes are available for the production of radioconjugates. Examples include: 211 At, 131 I, 125 I, 90 Y, 186 Re, 188 Re, 153 Sm, 212 Bi, 32 P, 212 Radioactive isotopes include Pb and Lu. When the radioactive conjugate is used for detection, the radioactive conjugate is a radioactive atom for scintigraphic examination (e.g., Tc-99m or 123 I), or spin labels (again, e.g., iodine-123, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese, or iron) for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, MRI).
[0185] Conjugates of antibodies and cytotoxic agents can be made using a variety of bifunctional protein linking agents, such as N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (e.g., dimethyl adipimidate HCl), active esters (e.g., disuccinimidyl suberate), aldehydes (e.g., glutaraldehyde), bis-azido compounds (e.g., bis(p-azidobenzoyl)hexanediamine), bis-diazonium derivatives (e.g., bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (e.g., toluene 2,6-diisocyanate), and bis-active fluorine compounds (e.g., 1,5-difluoro-2,4-dinitrobenzene). For example, ricin immunotoxins can be prepared as described in Vitetta et al., Science 238:1098 (1987). Carbon-14 labeled 1-isothiocyanatobenzyl-3-methyldiethylenetriaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionuclides to antibodies. See WO94 / 11026. The linker can be a "cleavable linker" that facilitates the release of the cytotoxic drug inside the cell. For example, an acid-labile linker, a peptidase-sensitive linker, a photolabile linker, a dimethyl linker, or a disulfide-containing linker (Chari et al., Cancer Res. 52:127-131 (1992); U.S. Patent No. 5,208,020) can be used.
[0186] The immunoconjugates or ADCs herein expressly contemplate, but are not limited to, conjugates prepared using cross-linking reagents including, but not limited to, BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and sulfo-SMPB, and SVSB (succinimidyl-(4-vinylsulfone)benzoate), which are commercially available (e.g., from Pierce Biotechnology, Inc., Rockford, IL., USA).
[0187] E. Methods and Compositions for Diagnostics and Detection In certain embodiments, any of the anti-target protein antibodies provided herein is useful for detecting the presence of target protein in biological samples.The term "detection" as used herein includes quantitative or qualitative detection.In certain embodiments, the biological sample comprises cells or tissues, such as cells or tissues of heart, liver, lung, kidney, spleen, colon, bone marrow.
[0188] In one embodiment, the antibody of the present disclosure is provided for use in a diagnostic method or a detection method. In a further aspect, a method of detecting the presence of a target protein in a biological sample is provided. In a particular embodiment, the method comprises contacting a biological sample with an antibody as described herein under conditions that allow the antibody described herein to bind to the target protein, and detecting whether a complex is formed between the antibody and the target protein. Such a method can be an in vitro method or an in vivo method. In one embodiment, the antibody of the present disclosure is used to select subjects suitable for treatment with the antibody of the present disclosure, for example, when the target protein is a biomarker for selecting patients.
[0189] Exemplary disorders that may be diagnosed using the antibodies of the present disclosure include cancers, such as lung cancer (eg, lung adenocarcinoma), colon cancer, and the like.
[0190] In certain embodiments, labeled anti-target protein antibodies are provided. Labels include, but are not limited to, directly detectable labels or moieties (e.g., fluorescent labels, chromogenic labels, electron-dense labels, chemiluminescent labels, and radioactive labels) as well as indirectly detectable moieties (e.g., enzymes or ligands) through, for example, enzymatic reactions or molecular interactions. Exemplary labels include, but are not limited to, the following: radioisotopes 32 P, 14 C. 125 I, 3 H and 131 I, fluorophores such as rare earth chelates or those linked to fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luciferases such as firefly luciferase and bacterial luciferase (U.S. Pat. No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, horseradish peroxidase (HRP), alkaline phosphatase, β-galactosidase, glucoamylase, lysozyme, monosaccharide oxidases (e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase), heterocyclic oxidases such as uricase and xanthine oxidase, enzymes that oxidize dye precursors using hydrogen peroxide (e.g., HRP, lactoperoxidase, or microperoxidase), biotin / avidin, spin labels, bacteriophage labels, stable free radicals, and the like.
[0191] F. Pharmaceutical Formulations In one aspect, the present disclosure provides a pharmaceutical formulation of the anti-target protein antibody described herein. In certain embodiments, the pharmaceutical formulation of the present disclosure is a cancer therapeutic agent, a cancer preventive agent, or a cancer diagnostic agent. Such a formulation is prepared by mixing the antibody with the desired purity with one or more optional pharma- ceutical acceptable carriers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)) in the form of a lyophilized formulation or an aqueous solution. Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to, the following: buffers such as phosphate, citrate, and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl, or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol, etc.; small (less than about 10 residues) polypeptides; proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrin; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or non-ionic surfactants such as polyethylene glycol (PEG). Exemplary pharmacologic carriers herein further include interstitial drug dispersing agents, such as soluble neutral activated hyaluronidase glycoproteins (sHASEGPs) (e.g., human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX®, Baxter International, Inc.)).Certain exemplary sHASEGPs and methods of their use (including rHuPH20) are described in U.S. Patent Application Publication Nos. 2005 / 0260186 and 2006 / 0104968. In one aspect, a sHASEGP is combined with one or more additional glycosaminoglycanases, such as chondroitinases.
[0192] Exemplary lyophilized antibody formulations are described in U.S. Patent No. 6,267,958. Aqueous antibody formulations include those described in U.S. Patent No. 6,171,586 and WO2006 / 044908, the latter formulations including a histidine-acetate buffer.
[0193] The formulations herein may contain more than one active ingredient as necessary for the particular indication to be treated or prevented. Those with complementary activities that do not adversely affect each other are preferred. For example, it may be desirable to provide an additional cytotoxic agent. Such active ingredients are present in suitable combinations in amounts that are effective for the intended purpose.
[0194] The active ingredient may be incorporated into microcapsules (e.g., hydroxymethylcellulose or gelatin microcapsules, and poly(methyl methacrylate) microcapsules, respectively) prepared, for example, by droplet formation (coacervation) techniques or by interfacial polymerization, into colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules), or into macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).
[0195] Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, eg, films, or microcapsules.
[0196] Preparations to be used for in vivo administration are typically sterile. Sterility is readily accomplished, for example, by filtration through sterile filtration membranes.
[0197] G. Therapeutic Methods and Compositions Any of the antibodies provided herein may be used in therapeutic methods. In one aspect, the antibody of the present disclosure is provided for use as a pharmaceutical. In a further aspect, the antibody of the present disclosure is provided for use in the treatment of cancer. In a particular embodiment, the antibody of the present disclosure is provided for use in a treatment method. In a particular embodiment, the antibody of the present disclosure is provided for use in a method of treating an individual with cancer (e.g., lung cancer, colon cancer), comprising administering to the individual an effective amount of the antibody of the present disclosure. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent (e.g., as described below). In a further embodiment, the antibody of the present disclosure is provided for use in inducing cytotoxic activity. In a particular embodiment, the antibody of the present disclosure is provided for use in a method of inducing cytotoxic activity in an individual, comprising administering to the individual an effective amount of the antibody of the present disclosure to induce cytotoxic activity. The "individual" according to any of the above embodiments is preferably a human.
[0198] In a further aspect, the present disclosure provides for the use of an antibody of the present disclosure in the manufacture or preparation of a medicament. In one embodiment, the medicament is for the treatment of cancer (e.g., lung cancer, colon cancer). In a further embodiment, the medicament is for use in a method of treating cancer (e.g., lung cancer, colon cancer), comprising administering an effective amount of the medicament to an individual having cancer (e.g., lung cancer, colon cancer). In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent (e.g., as described below). In a further embodiment, the medicament is for inducing cytotoxic activity. In a further embodiment, the medicament is for use in a method of inducing cytotoxic activity in an individual, comprising administering to the individual an effective amount of the medicament to induce cytotoxic activity. An "individual" according to any of the above embodiments may be a human.
[0199] In one embodiment of the above aspects, the present disclosure provides an antibody or pharmaceutical product of the present disclosure for use in treating lung cancer, comprising: assessing the presence or absence of one or more selected from EGFR driver mutations, BRAF driver mutations, ERBB2 driver mutations, ALK fusion gene expression, and RET / ROS1 fusion gene expression in a biological sample obtained from a lung cancer patient; selecting a lung cancer patient not having one or more selected from EGFR driver mutations, BRAF driver mutations, ERBB2 driver mutations, ALK fusion gene expression, and RET / ROS1 fusion gene expression as a responder to treatment with the antibody or pharmaceutical product of the present disclosure; and administering the antibody or pharmaceutical product of the present disclosure to the selected lung cancer patient. In another embodiment, the present disclosure provides an antibody or pharmaceutical product of the present disclosure for use in treating colon cancer, comprising assessing the presence or absence of KRAS mutations in a biological sample obtained from a colon cancer patient; selecting a colon cancer patient having a KRAS mutation as a responder to treatment with the antibody or pharmaceutical product of the present disclosure; and administering the antibody or pharmaceutical product of the present disclosure to the selected colon cancer patient. Methods for assessing the presence or absence of EGFR driver mutations, BRAF driver mutations, ERBB2 driver mutations, ALK fusion gene expression, RET / ROS1 fusion gene expression, and KRAS mutations are known in the art, and include, for example, the methods described in the Examples herein.
[0200] In a further aspect, the present disclosure provides a method of treating cancer (e.g., lung cancer, colon cancer) (synonymous with a method of treating an individual having cancer). In one embodiment, the method comprises administering to an individual having such cancer (e.g., lung cancer, colon cancer) an effective amount of an antibody of the present disclosure. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent (as described below). An "individual" according to any of the above embodiments may be a human.
[0201] In one embodiment of the above aspects, the method comprises: assessing the presence or absence of one or more of EGFR driver mutations, BRAF driver mutations, ERBB2 driver mutations, ALK fusion gene expression, and RET / ROS1 fusion gene expression in a biological sample obtained from an individual with lung cancer; selecting an individual who does not have one or more of EGFR driver mutations, BRAF driver mutations, ERBB2 driver mutations, ALK fusion gene expression, and RET / ROS1 fusion gene expression as a responder to treatment with an antibody of the disclosure; and administering an antibody of the disclosure to the selected individual. In another embodiment, the method comprises assessing the presence or absence of a KRAS mutation in a biological sample obtained from an individual with colorectal cancer; selecting an individual who has a KRAS mutation as a responder to treatment with an antibody of the disclosure; and administering an antibody of the disclosure to the selected individual.
[0202] In a further aspect, the present disclosure provides a method for inducing cytotoxic activity in an individual. In one embodiment, the method comprises administering to the individual an effective amount of an antibody of the present disclosure to induce cytotoxic activity. In one embodiment, the "individual" is a human.
[0203] In a further aspect, the present disclosure provides pharmaceutical formulations (e.g., for use in any of the therapeutic methods described above) comprising any of the antibodies provided herein. In one embodiment, the pharmaceutical formulation comprises any of the antibodies provided herein and a pharma- ceutically acceptable carrier. In another embodiment, the pharmaceutical formulation comprises any of the antibodies provided herein and at least one additional therapeutic agent (e.g., as described below).
[0204] The antibody of the present disclosure can be used alone or in combination with other agents in therapy.For example, the antibody of the present disclosure can be co-administered with at least one additional therapeutic agent.In certain embodiments, the additional therapeutic agent is a cytotoxic agent.
[0205] Combination therapy as described above includes combined administration (two or more therapeutic agents in the same or separate formulations) and separate administration, where administration of the antibody of the present disclosure may precede, be concurrent with, and / or be subsequent to administration of the additional therapeutic agent. In one embodiment, administration of the antibody of the present disclosure and administration of the additional therapeutic agent are performed within about one month, or within about one, two, or three weeks, or within about one, two, three, four, five, or six days of each other. The antibody of the present disclosure may also be used in combination with radiation therapy.
[0206] The antibodies of the present disclosure (and any additional therapeutic agents) may be administered by any suitable means, including parenteral, pulmonary, and nasal administration, and, if desired for localized treatment, intralesional administration. Parenteral injections include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Dosing may be by any suitable route, such as by injection, e.g., intravenous or subcutaneous injection, depending in part on whether administration is brief or chronic. Various dosing schedules are contemplated herein, including, but not limited to, single or repeated doses over various time periods, bolus administration, and pulse infusion.
[0207] The antibodies of the present disclosure are formulated, dosed, and administered in a manner consistent with good medical practice. Factors to be considered in this regard include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the schedule of administration, and other factors known to medical practitioners. The antibodies are optionally, but not necessarily, formulated with one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents depends on the amount of antibody present in the formulation, the type of disorder or treatment, and other factors discussed above. These are typically used in the same dosages and routes of administration as described herein, or about 1 to 99% of the dosages described herein, or in any dosage and by any route as empirically / clinically determined to be appropriate.
[0208] The appropriate dose of the antibody of the present disclosure (when used alone or with one or more other additional therapeutic agents) for the prevention or treatment of disease will depend on the type of disease being treated, the type of antibody, the severity and course of the disease, whether the antibody is administered for prophylactic or therapeutic purposes, medical history, the patient's clinical history and response to the antibody, and the discretion of the attending physician. The antibody is suitably administered to the patient at one time or over a series of treatments. Depending on the type and severity of the disease, for example, about 1 μg / kg to 15 mg / kg (e.g., 0.1 mg / kg to 10 mg / kg) of antibody may be the initial candidate dose for administration to the patient, whether by one or more separate administrations or by continuous infusion. One typical daily dose may range from about 1 μg / kg to 100 mg / kg or more, depending on the factors mentioned above. In the case of repeated administration over several days or longer, depending on the circumstances, treatment is usually maintained until a desired suppression of disease symptoms occurs. One exemplary dose of the antibody is within the range of about 0.05 mg / kg to about 10 mg / kg. Thus, one or more doses of about 0.5 mg / kg, 2.0 mg / kg, 4.0 mg / kg, or 10 mg / kg (or any combination thereof) may be administered to the patient. Such doses may be administered intermittently, for example, every week or every three weeks (e.g., such that the patient receives about 2 to about 20, or, for example, about 6 doses of the antibody). A high initial loading dose may be administered, followed by one or more lower doses. However, other dosing regimens may also be useful. The progress of this therapy is easily monitored by conventional techniques and measurements.
[0209] It will be understood that any of the above-described formulations or therapeutic methods may be practiced using the immunoconjugates of the present disclosure in place of, or in addition to, the antibodies of the present disclosure.
[0210] H.Product In another aspect of the disclosure, an article of manufacture is provided that includes materials useful for the treatment, prevention, and / or diagnosis of the above-mentioned disorders. The article of manufacture includes a container and a label on the container or a package insert associated with the container. Preferred containers include, for example, bottles, vials, syringes, IV solution bags, and the like. The containers may be formed from a variety of materials, such as glass or plastic. The container may hold the composition alone or in combination with another composition effective for the treatment, prevention, and / or diagnosis of a condition, and may have a sterile access port (e.g., the container may be an intravenous solution bag or vial having a stopper pierceable by a hypodermic needle). At least one active ingredient in the composition is an antibody of the disclosure. The label or package insert indicates that the composition is used for treating the condition of choice. The article of manufacture may further comprise: (a) a first container with a composition comprising an antibody of the present disclosure contained therein; and (b) a second container with a composition comprising an additional cytotoxic or otherwise therapeutic agent contained therein. The article of manufacture in this aspect of the disclosure may further comprise a package insert indicating that the composition may be used to treat a particular condition. Alternatively or additionally, the article of manufacture may further comprise a second (or third) container comprising a pharma- ceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate buffered saline, Ringer's solution, and dextrose solution. It may further comprise other equipment desirable from a commercial or user standpoint, such as other buffers, diluents, filters, needles, and syringes.
[0211] It will be understood that any of the above-mentioned products may include an immunoconjugate of the present disclosure instead of or in addition to an antibody of the present disclosure. EXAMPLES
[0212] Example 1: Human tissue and its genetic analysis (1-1) Obtaining colon cancer tissue, lung cancer tissue, adjacent normal tissue, and normal tissue Human tissues to be analyzed were purchased from Asterand, ILS bio, and All cells. As colon cancer tissues and normal tissues adjacent to colon cancer tissues, 12 sets of colon cancer tissues and normal tissues adjacent to colon cancer tissues from the same donor (stage III or IV) (total of 24 specimens from 12 donors) were obtained, and two specimens of lymph node metastasis cancer tissues from two of the 12 donors were also obtained, totaling 28 specimens.
[0213] We obtained 14 lung adenocarcinoma tissues and 10 normal tissues adjacent to lung adenocarcinoma as lung cancer tissues and adjacent normal tissues. Of these, there were two sets of cancer tissues and adjacent normal tissues from the same donor, and the rest were not from the same donor. As normal tissues, triplicate normal tissues or adjacent normal tissues from the heart, liver, lung, kidney, spleen, colon, and bone marrow were obtained.
[0214] (1-2) ALK, RET fusion gene analysis of human lung cancer tissues (RNA-seq analysis) In order to examine whether the lung cancer tissue obtained in Example 1-1 has a driver fusion gene (ALK, RET / ROS1), RNA-seq analysis (Takara Bio Inc.) was performed. Total RNA was extracted from 2-3 pieces of tissue with a size of about 3 mm using NucleoSpinTissue (Mach-Lei-Nagel) according to the method recommended by the manufacturer. A DNA library was prepared from the total RNA sample using TruSeq RNA Sample Prep Kit v2 (Illumina) according to the method recommended by the manufacturer. The prepared DNA libraries were mixed and subjected to 1-lane, 100-base both-end sequence analysis using an Illumina sequencer HiSeq, and the base sequence (read sequence) was obtained using the software attached to the sequencer. Fusion gene analysis was performed using STAR-Fusion (https: / / github.com / STAR-Fusion / STAR-Fusion). As a result, it was revealed that of the 14 lung cancer tissue samples obtained, none had the RET / ROS1 fusion gene, but one case (485475RF) had the ALK fusion gene (Table 2).
[0215] (1-3) Driver mutation analysis of human colon cancer and lung cancer tissues (Exome-seq analysis) Exome-seq analysis (Takara Bio Inc.) was performed to examine whether the cancer tissue obtained in Example 1-1 had driver mutations (KRAS, EGFR, BRAF, ERBB2). Genomic DNA was extracted from 2 to 3 pieces of tissue approximately 3 mm in size using NucleoSpinTissue (Machrey-Nagel) according to the method recommended by the manufacturer. A DNA library was prepared from the genomic DNA sample using SureSelect XT Human All Exon V6 (Agilent) according to the method recommended by the manufacturer. The prepared DNA libraries were mixed and 100 base both ends were analyzed using an Illumina sequencer HiSeq, and the base sequence (read sequence) was obtained using the software attached to the sequencer. Mutation analysis was performed using the CLC Genomics Server (QIAGEN). As a result, it was revealed that seven of the colon cancer tissue samples from 12 donors (1170614F, 1171659F, 39694FT, 39697FT, 39698FT, 39705FT, 40644FT) had KRAS driver mutations. In addition, it was revealed that three lung cancer tissue samples had EGFR driver mutations (1191924F, 1160304F, 1245371F), two had BRAF driver mutations (1186142F, 1209913F), and three had KRAS driver mutations (1177695F, 1185682F, 463102XF) (Table 2).
[0216] [Table 2] The detected driver mutations are summarized in Table 2. ILS40636FM1, ILS40636FM2, ILS40644FM1, and ILS40644FM2 are the results for cancer tissues that had metastasized to lymph nodes, while the others are the results for colorectal cancer and lung cancer tissues.
[0217] (Example 2) Protein expression analysis of human tissues (proteomics analysis) The tissue block obtained in Example 1-1 was placed in a mortar containing liquid nitrogen in a frozen state and pounded with a pestle to form tissue fragments of about 3 mm in size. Two to three pieces of the tissue fragments were transferred to a tube and finely crushed using a Multi-Beads Shocker (Yasui Kikai). The crushed tissue was added with tissue dissolution buffer (2% deoxycholic acid / 100 mM ammonium bicarbonate, Protease inhibitor cocktail (Roche), PhosSTOP (Roche)), and ultrasonically disrupted using an Acoustic Solubilizer (Covaris) or Bioruptor (Sonic Bio Co., Ltd.), and insoluble matter was removed by centrifugation at 15,000 rpm for 30 minutes, and the supernatant was collected and used as a tissue extract. After washing the bone marrow with PBS, tissue dissolution buffer was added to the precipitated cells, and tissue extracts were obtained in the same manner as for other tissues.
[0218] Proteins in the tissue extract were reduced with dithiothreitol and alkylated with iodoacetamide, and then precipitated by TCA / acetone precipitation. Proteins were dissolved in 8M urea / 400mM ammonium bicarbonate solution, and the protein lysate was diluted 4-fold with distilled water. The diluted protein lysate was digested with lysyl endopeptidase and trypsin using a REDS (Rapid Enzyme Digestion System) (AMR Corporation) to obtain a peptide solution. The peptide solution was desalted using Monospin C18 (GL Science) according to the method recommended by the manufacturer. The desalted peptide solution was then purified by Pierce TMFractionation was performed using the High pH Reversed-Phase Peptide Fractionation Kit (ThermoFisher Scientific) or AssayMAP Bravo cartridge RP-S (Agilent) according to the method recommended by the manufacturer, and each fraction was analyzed using an LC-MS analysis system consisting of a nano-LC system (Ultimate3000, Dionex) connected to a Q-Exactive (ThermoFisher Scientific). Raw data from LC-MS analysis was used to perform database search using MaxQuant (http: / / www.biochem.mpg.de / 5111795 / maxquant), proteins were identified, and quantitative values (iBAQ) were obtained. The database search was performed with the following parameters: Taxonomy: uniprot human, Fixed modification: carbamidomethylation (C), Variable modification: oxidation (M); deamidation (NQ), Acetyl (protein N-term), FDR (protein, peptide) <1%. The MaxQuant output file “proteinGroups.txt” was processed as follows to calculate quantitative values. 1. The signal intensities of protein groups assigned to the same gene are summed to calculate the gene-level intensity. 2. For each gene, the intensity is normalized by the number of fragments that can be generated by trypsin treatment and an iBAQ score is calculated. 3. For each sample, normalization is performed so that the average score is 1,000,000.
[0219] In total, over 10,000 proteins were identified and iBAQ values were obtained for each protein. Seven cell surface proteins with high expression in cancer and low expression in adjacent normal tissues and normal tissues (SPINT2, MARVELD3, MANSC1, NOX1, SLC12A2, CDCP1, CEACAM5) from colorectal cancer and 10 proteins (SPINT2, PVRL4, SEZ6L2, XPR1, FLVCR1, SLC7A5, STEAP1, MMP14, TNFRSF21, TMPRSS4) from lung cancer were selected as target antigen candidates.
[0220] The expression of the selected candidate proteins is shown in Figure 1-1 to Figure 1-16. In the analysis of colon cancer samples, CEACAM5 (SEQ ID NO: 10) is an antigen currently undergoing clinical trials, and serves as an index for comparing the expression profiles of antigens. CEACAM5 is expressed to a certain extent in normal tissues and adjacent normal tissues, but in almost all cancer cases, it was expressed at a higher level. NOX1, MARVELD3, and MANSC1 protein expression was not confirmed in normal tissues, but were highly expressed (above the median) in 3 to 4 colon cancer tissues with KRAS mutations, and a large difference was observed between the expression levels in colon cancer tissues and adjacent normal tissues, showing an expression profile different from that of CEACAM5. SPINT2, SLC12A2, and CDCP1 are expressed to a certain extent in normal tissues and in normal tissues adjacent to colon cancer tissues, but were expressed at a higher level in colon cancer tissues, showing an expression profile similar to that of CEACAM5. In the analysis of lung cancer samples, PVRL4 (SEQ ID NO: 11) is undergoing clinical trials, and serves as an index for comparing the expression profiles of antigens. PVRL4 and XPR1 were highly cancer-specific antigens, with no protein expression in normal tissues and high expression in lung cancer tissues. TMPRSS4 and TNFRSF21 were not expressed in normal tissues, but were expressed at moderate levels in lung cancer tissues. SLC7A5, STEAP1, FLVCR1, SEZ6L2, MMP14, and SPINT2 were expressed to some extent in normal tissues and in normal tissues adjacent to lung cancer tissues, but were expressed at higher levels in lung cancer tissues.
[0221] (Example 3) Isoform expression analysis of MARVELD3, a candidate target antigen from colon cancer MARVELD3 is known to exist in two isoforms, 1 and 2, whose intracellular domain amino acid sequences are very similar, but whose extracellular domains are significantly different (Figure 2).
[0222] To determine which isoform was highly expressed in cancer tissues, the peak intensities in LC-MS of peptide fragments of MARVELD3 identified in the proteomics analysis were confirmed. The list of identified peptides and the quantitative values were obtained using ModificationSpecificPeptides.txt, one of the MaxQuant output files analyzed in Example 1-2. In addition to the peptide fragments common to isoforms 1 and 2, isoform 2-specific fragments were detected in 4 out of 7 colon cancer tissue specimens with KRAS mutations (more than 2 out of 3 LC-MS analyses), and none of the adjacent normal tissues were detected more than 2 out of 3 (Figure 3-1). Isoform 1-specific fragments were detected in 2 out of 7 colon cancer tissue specimens with KRAS mutations (Figure 3-2). Therefore, it was inferred that isoform 2 is highly expressed in more colon cancer tissues with KRAS mutations.
[0223] (Example 4) Analysis of cell surface localization of candidate target antigens To confirm the cell surface localization of XPR-1, MARVELD3 (isoform 2), and NOX1, cell surface proteomics analysis was performed using Expi293 cells (ThermoFisher Scientific) overexpressing myc-tagged XPR-1 and MARVELD3 (isoform 2) using ExpiFectamine (ThermoFisher Scientific) according to the manufacturer's recommended method, and C2BBe1, SW403, SW1463, DMS79 (ATCC), and HLC-1 cells (Riken), which are presumed to highly express these three proteins. After washing with PBS, the cells were incubated with a cell membrane-impermeable biotin reagent (Sulfo-NHS-LC-biotin, ThermoFisher Scientific) to biotin-label the N-terminus and lysine side chain amino groups of the cell surface proteins. The collected cells were ultrasonically disrupted using a Covaris Acoustic Solubiliser or Bioruptor (Sonic Bio, Inc.) to obtain cell extracts.
[0224] Proteins in the cell extract were precipitated by the methanol / chloroform method and dissolved in 8M urea / 400mM ammonium bicarbonate solution. After reduction with dithiothreitol and alkylation with iodoacetamide, the proteins were digested with trypsin to obtain a peptide solution. The peptide solution was mixed with Neutravidin FG beads (Tamagawa Seiki), washed, and then eluted to purify the biotinylated peptides. The purified biotinylated peptides were analyzed using an LC-MS analysis system consisting of a nano-LC system (Ultimate3000, Dionex) connected to a Q-Exactive (ThermoFisher Scientific) or Orbitrap fusion Lumos (ThermoFisher Scientific). Using the raw data after LC-MS analysis, a database search was performed using MaxQuant (http: / / www.biochem.mpg.de / 5111795 / maxquant) to identify biotinylated peptides and proteins and obtain quantitative values. The database search was performed with the following parameters: Taxonomy: uniprot human, Fixed modification: carbamidomethylation (C), Variable modification: oxidation (M), Acetyl (Protein N-term), NHS-LC-biotin (N-term); NHS-LC-biotin (K), FDR (protein, peptide) <1%. The list of identified peptides and quantitative values were obtained from ModificationSpecificPeptides.txt, one of the output files of MaxQuant. From the sequence and expression level of the biotinylated peptides detected by this method, it is possible to determine whether the target protein is expressed on the cell membrane and to identify the extracellular region.
[0225] Biotinylated peptides of amino acid numbers 1-108, 111-122, 159-171, 177-216, 423-448, 473-502, 660-670, and 674-696 were detected in XPR1 overexpressing cells (Fig. 4). Biotinylated peptides of amino acid numbers 177-190, 428-448, and 660-670 were also detected in endogenous proteins of HLC-1 and DMS-79 cells (Fig. 4-1). This confirmed that XPR1 is localized on the cell surface, and suggested that the region that is considered to be the intracellular region by uniprot is the extracellular region.
[0226] NOX1 was confirmed to be localized on the cell surface because biotinylated peptides of amino acids 44-54, 131-161, and 242-258 were detected in C2BBe1, SW1463, and SW403 cells (Figure 4-2).
[0227] Although biotinylated peptides of amino acid numbers 101-111 and 163-198 were detected in overexpressing cells, biotinylated peptides of endogenous proteins were not detected in the analyzed cells (Figure 4-3). The part considered to be the extracellular domain of MARVELD3 isoform 2 has a small number of lysines that can be biotin-labeled, which may make it difficult to detect biotinylated peptides.
[0228] (Example 5) Protein expression analysis of cell lines (proteomics analysis) HLC-1 cells (Riken), NCI-H2227 cells (ATCC), and Caco-2 cells (Riken) were suspended in cell lysis buffer (1% NP-40, 50 mM Tris-Cl (pH 7.5), 150 mM NaCl, protease inhibitor cocktail (Roche)) and sonicated using an acoustic lysator (Covaris) to obtain cell extracts. Proteins in the cell extract were reduced with dithiothreitol, alkylated with iodoacetamide, and precipitated by methanol / chloroform precipitation. The precipitated proteins were dissolved in 8 M urea / 400 mM ammonium bicarbonate solution, diluted 4-fold with distilled water, and digested with lysyl endopeptidase and trypsin to obtain a peptide solution. The peptide solution was desalted using Monospin C18 (GL Science) according to the method recommended by the manufacturer. The desalted peptide solution was then fractionated using AssayMAP Bravo cartridge RP-S (Agilent) according to the method recommended by the manufacturer, and each fraction was analyzed using an LC-MS analysis system consisting of a nano-LC system (ThermoFisher Scientific) connected to a Q-Exactive (ThermoFisher Scientific). Raw data after LC-MS analysis was subjected to database search using MaxQuant (http: / / www.biochem.mpg.de / 5111795 / maxquant), proteins were identified, and quantitative values (iBAQ, Intensity Based Absolute Quantification) were obtained. The database search was performed with the following parameters: Taxonomy: uniprot human, Fixed modification: carbamidomethylation (C), Variable modification: oxidation (M); deamidation (NQ), Acetyl (protein N-term), FDR (protein, peptide) <1%. The iBAQ values of XPR1 and MARVELD3 listed in the MaxQuant output file “proteinGroups.txt” are shown in Figure 5-1 and Figure 5-2.
[0229] (Example 6) Preparation of anti-XPR1 antibody A plasmid vector was constructed to express a molecule (human XPR1-TT, base sequence number 23, amino acid sequence number 24) in which a TT peptide sequence (FNNFTVSFWLRVPKVSASHLE, sequence number: 22) was added to the C-terminus of the full-length human XPR1 (sequence number: 1). Four New Zealand white rabbits (Kitayama Labes) were immunized six times with the constructed plasmid vector by gene gun method and in vivo electroporation method, and peripheral blood mononuclear cells and splenocytes were collected from the rabbits one week after the final immunization. Surface IgG-positive B cells were enriched and cultured from the collected rabbit-derived cells using MACS with PE-labeled anti-rabbit IgG antibody (Southern biotech). Among the cultured B cells, B cells secreting antibodies that bind to human XPR1 were identified using a fluorescent microscope attached to a micromanipulator CellCelector (ALS) and collected into a microwell plate using a micromanipulator CellCelector (ALS). Genes constituting the variable region of rabbit immunoglobulin were cloned from the collected B cells by RT-PCR. These DNA fragments of the variable regions of rabbit immunoglobulins were inserted into expression vectors containing IgG constant regions to produce recombinant antibodies. Anti-human XPR1 antibodies were prepared by methods known to those skilled in the art. The prepared anti-human XPR1 antibodies are shown in Table 3.
[0230] [Table 3]
[0231] As an anti-human CD3 antibody, CE115TR (heavy chain variable region SEQ ID NO: 65, light chain variable region SEQ ID NO: 66), which binds to the CD3ε chain constituting the T cell receptor to induce an activation signal of the T cell receptor, was prepared by a method known to those skilled in the art. The present inventors prepared a bispecific antibody consisting of an anti-human XPR1 antibody and an anti-CD3 antibody by a method known to those skilled in the art. The prepared anti-human XPR1 / anti-human CD3 bispecific antibody is shown in Table 4. The heavy chain constant region sequence of the anti-human XPR1 side of the bispecific antibody is the sequence shown in SEQ ID NO: 83, the light chain constant region sequence of the anti-human XPR1 side is the sequence shown in SEQ ID NO: 85, the heavy chain constant region sequence of the anti-human CD3 side is the sequence shown in SEQ ID NO: 84, and the light chain constant region sequence of the anti-human CD3 side is the sequence shown in SEQ ID NO: 86.
[0232] [Table 4]
[0233] (Example 7) Confirmation of binding of anti-human XPR1 antibody to human XPR1 A plasmid vector was constructed to express in mammalian cells a molecule (human XPR1-Myc, base sequence: 26, amino acid sequence: 27) in which a Myc tag sequence (EQKLISEEDL, sequence: 25) was added to the C-terminus of full-length human XPR1 (amino acid sequence: 1). The constructed plasmid vector was introduced into Expi293 cells (Thermo Fisher Scientific) to transiently express the protein in the Expi293 cells. At the same time, Expi293 cells into which an empty plasmid vector was introduced were also prepared as a control. The Expi293 cells into which an empty plasmid vector was introduced were stained with CellTrace FarRed (Thermo Fisher Scientific), mixed with Expi293 cells expressing human XPR1-Myc, and then reacted with the anti-human XPR1 antibody prepared in Example 6. Then, anti-human IgG Fc cross-adsorbed Alexa488 (Invitrogen) was reacted to stain the anti-human XPR1 antibody. Dead cells were stained with DAPI (Sigma-Aldrich). Cells reacted with the antibody were measured using FACS Aria III (Becton, Dickinson and Company). The obtained data was analyzed using FlowJo ver.10. The live cell fraction that was not stained with DAPI fluorescence was divided into a fraction stained with CellTrace FarRed (cells into which an empty plasmid vector was introduced) and a fraction not stained with CellTrace FarRed (cells into which a human XPR1-Myc expression plasmid vector was introduced), and when the Alexa488 staining of each was confirmed, the fraction not stained with CellTrace FarRed (cells into which a human XPR1-Myc expression plasmid vector was introduced) showed predominant Alexa488 staining compared to the fraction stained with CellTrace FarRed (cells into which an empty plasmid vector was introduced) (Figure 6). From this, it was confirmed that the anti-human XPR1 antibody prepared in Example 6 binds to human XPR1 expressed in cells.
[0234] Example 8: Cytotoxicity assay of anti-human XPR1 / anti-human CD3 bispecific antibodies LDH cytotoxicity assay using human PBMC (peripheral blood mononuclear cells) The cytotoxic activity of the anti-human XPR1 / anti-human CD3 bispecific antibody prepared in Example 6 was evaluated by the LDH release method (LDH Cytotoxicity Detection Kit: TAKARA). First, 50 μL of antibody solution at each concentration (0.04, 0.004, 0.0004 mg / mL) diluted to a final concentration of 4 times with culture medium (RPMI1640 with 10% FBS) was added to each well of a 96-well U-bottom plate. Next, as target cells, HLC-1 was adjusted to 1x10E5 cells / mL and NCI-H2227 was adjusted to 2x10E5 cells / mL, and 100 μL / well or 50 μL / well was seeded so that the final cell number in each well was 1x10^4 cells / well, and the U-bottom plate was left to stand at room temperature for 15 minutes. As effector cells, human PBMC (peripheral blood mononuclear cells) were adjusted to 4x10E6 cells / mL or 2x10E6 cells / mL, and 50 μL of 4x10E6 cells / mL was added to the wells seeded with HLC-1 cells, and 2x10E6 cells / mL was added to the wells seeded with NCI-H2227 cells. Then, the U-bottom plate was left to stand at 37°C for about 24 hours in a 5% carbon dioxide incubator and centrifuged. In addition to the wells to which the target cells, effector cells, and antibodies were added, wells to which only culture medium was added, wells to which only target cells and effector cells were added (no antibody was added), and wells to which target cells, effector cells, and Triton X-100 were added (no antibody was added) were also prepared in the U-bottom plate. 100 μL of culture supernatant from each well of the U-bottom plate was transferred to a 96-well flat-bottom plate. Catalyst solution was added to 1 mL of H 2 The catalyst solution was dissolved in 0 and mixed with the dye solution at a catalyst solution:dye solution ratio of 1:45. The mixture of the catalyst solution and the dye solution was dispensed into the 96-well flat-bottom plate to which the culture supernatant had been transferred, and the flat-bottom plate was left to stand at room temperature for 15-30 minutes. The absorbance at 492 nm of each well was measured, and the absorbance at 492-620 nm was calculated using the absorbance at 620 nm of the control wave measured at the same time. The cell proliferation inhibition rate (cytotoxicity) was calculated by applying the absorbance at 492-620 nm of each well to the following formula. TIFF2024156868000005.tif11170A: Absorbance at 492-620 nm for wells containing target cells, effector cells, and antibodies B: Absorbance at 492-620 nm in wells containing only target and effector cells C: Absorbance at 492-620 nm in wells containing target cells, effector cells, and Triton X-100 D: Average absorbance at 492-620 nm for wells containing culture medium only (blank) The anti-human XPR1 / anti-human CD3 bispecific antibody exhibited dose-dependent cell proliferation inhibitory activity (FIGS. 7 and 8).
[0235] (Example 9) Preparation of anti-human MARVELD3 isoform 2 antibody A plasmid vector expressing human MARVELD3 isoform2 (nucleotide sequence: 28, amino acid sequence: 4) was constructed. Four New Zealand white rabbits (Kitayama Labes) were immunized six times with the constructed plasmid vector by gene gun method and in vivo electroporation method, and peripheral blood mononuclear cells and splenocytes were collected from the rabbits one week after the final immunization. Surface IgG-positive B cells were enriched from the collected rabbit-derived cells by MACS using PE-labeled anti-rabbit IgG antibody (Southern biotech) and cultured. Among the cultured B cells, B cells secreting antibodies that bind to human MARVELD3 isoform2 were identified using a fluorescent microscope attached to a micromanipulator CellCelector (ALS) and collected into a microwell plate using a micromanipulator CellCelector (ALS). Genes constituting the variable regions of rabbit immunoglobulins were cloned from the collected B cells by RT-PCR. DNA fragments of the variable regions of these rabbit immunoglobulins were inserted into expression vectors containing IgG constant regions to prepare recombinant antibodies. Anti-human MARVELD3 isoform 2 antibodies were prepared by methods known to those skilled in the art. The prepared anti-human MARVELD3 isoform 2 antibodies are shown in Table 5.
[0236] [Table 5]
[0237] As an anti-human CD3 antibody, CE115TR (heavy chain variable region SEQ ID NO: 65, light chain variable region SEQ ID NO: 66), which binds to the CD3ε chain constituting the T cell receptor to induce an activation signal of the T cell receptor, was prepared by a method known to those skilled in the art. The present inventors prepared a bispecific antibody consisting of an anti-human MARVELD3 isoform2 antibody and an anti-CD3 antibody by a method known to those skilled in the art. The prepared anti-human MARVELD3 isoform2 / anti-human CD3 bispecific antibody is shown in Table 6. The heavy chain constant region sequence of the anti-human MARVELD3 isoform2 side of the bispecific antibody is the sequence shown in SEQ ID NO: 83, the light chain constant region sequence of the anti-human MARVELD3 isoform2 side is the sequence shown in SEQ ID NO: 85, the heavy chain constant region sequence of the anti-human CD3 side is the sequence shown in SEQ ID NO: 84, and the light chain constant region sequence of the anti-human CD3 side is the sequence shown in SEQ ID NO: 86.
[0238] [Table 6]
[0239] (Example 10) Confirmation of binding of anti-human MARVELD3 isoform 2 antibody to MARVELD3 isoform 2 A plasmid vector expressing a molecule (Myc-human MARVELD3, base sequence SEQ ID NO: 29, amino acid sequence SEQ ID NO: 30) in mammalian cells, in which a Myc tag sequence (EQKLISEEDL, SEQ ID NO: 25) was added after the N-terminal methionine of human MARVELD3 isoform2 full length (amino acid sequence SEQ ID NO: 4), was introduced into Expi293 cells (Thermo Fisher Scientific), and the protein was transiently expressed in Expi293 cells. At the same time, Expi293 cells into which an empty plasmid vector was introduced were also prepared as a control. After the Expi293 cells into which the empty plasmid vector was introduced were stained with CellTrace FarRed (Thermo Fisher Scientific), they were mixed with Expi293 cells expressing human MARVELD3 isoform2, and then reacted with the anti-human MARVELD3 isoform2 antibody prepared in Example 9. Then, anti-human IgG Fc cross-adsorbed Alexa488 (Invitrogen) was reacted and anti-human MARVELD3 isoform2 antibody was stained. Dead cells were stained with DAPI (Sigma-Aldrich). Antibody-reacted cells were measured using FACS Aria III (Becton, Dickinson and Company). The obtained data was analyzed using FlowJo ver.10. The live cell fraction that was not stained with DAPI fluorescence was divided into a fraction stained with CellTrace FarRed (empty plasmid vector-transfected cells) and a fraction not stained with CellTrace FarRed (human XPR1-Myc expression plasmid vector-transfected cells), and Alexa488 staining for each was confirmed. The fraction not stained with CellTrace FarRed (human MARVELD3 isoform2 expression plasmid vector-transfected cells) showed predominant Alexa488 staining compared to the fraction stained with CellTrace FarRed (empty plasmid vector-transfected cells) (Figure 9). From this, it was confirmed that the anti-human MARVELD3 isoform 2 antibody prepared in Example 9 binds to human MARVELD3 isoform 2 expressed in cells.
[0240] (Example 11) Cytotoxicity assay of anti-human MARVELD3 isoform2 / anti-human CD3 bispecific antibody Cytotoxicity assay using human peripheral blood mononuclear cells The cytotoxic activity of the anti-human MARVELD3 isoform2 / anti-human CD3 bispecific antibody prepared in Example 9 was evaluated based on the cell proliferation inhibition rate determined using an xCELLigence real-time cell analyzer (Roche Diagnostics). The target cells used were Caco-2 cells. First, 50 μL of medium was added to each well of an E-Plate 96 (Roche Diagnostics) plate. Caco-2 cells were detached from the dish and 1.3 x 10 3 Cells / well (50 μl / well) were seeded. Live cell assays were then initiated using the xCELLigence Real-Time Cell Analyzer. The next day, the plate was removed from the xCELLigence Real-Time Cell Analyzer and 50 μL of each antibody prepared at various concentrations (0.1, 1.0, 10 μg / mL) was added to each well of the plate. 50 μL of human PBMC suspension (5 x 10 4 Further addition of 1000 cells / well was performed. The plate was placed again in the xCELLigence Real-time Cell Analyzer and the viability assay was started. The reaction was carried out at 37°C under 5% carbon dioxide. The percentage of cell proliferation inhibition was determined using the Cell Index value 72 hours after addition of human PBMCs according to the formula shown below. The Cell Index value used in the calculation was normalized so that the Cell Index value immediately before the addition of the antibody was 1. TIFF2024156868000008.tif11170A shows the average Cell Index value of wells without antibody (target cells and human PBMCs only), and B shows the average Cell Index value of each well. Measurements were repeated three times. The cytotoxic activity of anti-KLH / CD3 bispecific antibodies, TR01H113 / / MDA0279 and TR01H113 / / MDA0314, was measured using PBMCs (peripheral blood mononuclear cells). Compared to the control anti-KLH / CD3 bispecific antibody, TR01H113 / / MDA0279 and TR01H113 / / MDA0314 showed high cell proliferation inhibition rates (Figure 10).
[0241] Example 12: Preparation of human NOX1 protein A gene encoding a molecule (human NOX1-Strep, amino acid sequence: 34) with the Twin-Strep tag sequence (WSHPQFEKGGGSGGGSGGSAWSHPQFEK, SEQ ID NO: 31) added to the C-terminus of the full-length human NOX1 sequence (amino acid sequence: 2) was synthesized and cloned into a mammalian cell expression vector. The protein was transiently expressed by introducing this expression vector into Expi293 cells (Thermo Fisher Scientific). The cells were harvested by centrifugation, and a final concentration of 1% Fos-choline 14 / 0.2% Cholesterol hemisuccinate was added to solubilize the human NOX1-Strep protein. The solubilized protein sample was purified by affinity chromatography using Strep-Tactin XT Superflow (IBA GmbH). The fractions containing human NOX1-Strep protein were collected, and a final concentration of 2 mg / mL Amphipol A8-35 solution (Anatrace) was added. Immediately after addition of Bio-Beads SM-2 Adsorbent Media (BIO-RAD), the cells were incubated at 4°C for 12-16 hours to remove Fos-choline 14 / Cholesterol hemisuccinate and reconstitute the human NOX1-Strep protein in Amphipol A8-35. The reconstituted human NOX1--Strep protein sample was purified by gel filtration chromatography using a Superdex 200 increase 10 / 300 column (GE Healthcare). Fractions containing human NOX1--Strep protein were collected and concentrated using a 50 kDa MWCO ultrafiltration membrane. Amphipol A8-35 was added to the concentrated sample at a final concentration of 2 mg / mL to obtain the final preparation.
[0242] (Example 13) Preparation of anti-human NOX1 antibody Two New Zealand white rabbits (Kitayama Labes) were immunized four times using the human NOX1-Strep protein prepared in Example 12, and peripheral blood mononuclear cells and splenocytes were collected from the rabbits six days after the final immunization. A gene encoding a molecule (NOX1_Nx1B_564-myc, base sequence: 32, amino acid sequence: 33) was synthesized by fusing the signal sequence and transmembrane domain of Neurexin 1B-delta to the N-terminus of the 1st to 564th amino acids of human NOX1 (SEQ ID NO: 2) (Cell. 2018 Nov 1; 175(4): 1131-1140.e11.) and adding a Myc tag sequence (EQKLISEEDL) to the C-terminus, and cloned into a plasmid vector for mammalian cell expression. Eight New Zealand white rabbits (Kitayama Labes) were immunized six times using the constructed plasmid vector by gene gun method and Tropis (PharmaJet) device, and splenocytes were collected from the rabbits 6 or 7 days after the final immunization. Surface IgG-positive B cells were enriched from the collected rabbit-derived cells using PE-labeled anti-rabbit IgG antibody (Southern biotech) by MACS and FACS, and cultured. Among the cultured B cells, B cells secreting antibodies that bind to human NOX1 were identified using a fluorescent microscope attached to a micromanipulator CellCelector (ALS), and collected into a microwell plate using a micromanipulator CellCelector (ALS). Genes constituting the variable regions of rabbit immunoglobulins were cloned from the collected B cells by RT-PCR. DNA fragments of the variable regions of these rabbit immunoglobulins were inserted into an expression vector containing an IgG constant region to produce recombinant antibodies. Anti-human NOX1 antibodies were prepared by methods known to those skilled in the art. The prepared anti-human NOX1 antibodies are shown in Table 7.
[0243] [Table 7]
[0244] As an anti-human CD3 antibody, CE115TR (heavy chain variable region SEQ ID NO: 65, light chain variable region SEQ ID NO: 66), which binds to the CD3ε chain constituting the T cell receptor to induce an activation signal of the T cell receptor, was prepared by a method known to those skilled in the art. The present inventors prepared a bispecific antibody consisting of an anti-human NOX1 antibody and an anti-CD3 antibody by a method known to those skilled in the art. The prepared anti-human NOX1 / anti-human CD3 bispecific antibody is shown in Table 8. The heavy chain constant region sequence of the anti-human NOX1 side of the bispecific antibody is the sequence shown in SEQ ID NO: 83, the light chain constant region sequence of the anti-human XPR1 side is the sequence shown in SEQ ID NO: 85, the heavy chain constant region sequence of the anti-human CD3 side is the sequence shown in SEQ ID NO: 84, and the light chain constant region sequence of the anti-human CD3 side is the sequence shown in SEQ ID NO: 86.
[0245] [Table 8]
[0246] (Example 14) Confirmation of binding of anti-human NOX1 antibody to human NOX1 Plasmid vectors expressing human NOX1-Strep (amino acid sequence number: 34) or NOX1_Nx1B_564-myc (amino acid sequence number: 33) were introduced into Expi293 cells (Thermo Fisher Scientific) to transiently express the protein. At the same time, Expi293 cells into which an empty plasmid vector was introduced were also prepared as a control. These cells were treated with 4% paraformaldehyde and 1% digitonin. Expi293 cells into which an empty plasmid vector was introduced were stained with CellTrace FarRed (Thermo Fisher Scientific), and Expi293 cells into which a plasmid vector expressing human NOX1-Strep was introduced were stained with CellTrace FarRed and CellTrace Violet (Thermo Fisher Scientific), and then mixed with Expi293 cells expressing NOX1_Nx1B_564-myc, and reacted with the anti-human NOX1 antibody prepared in Example 13. The cells were then stained with anti-human NOX1 antibody by reaction with anti-human IgG Fc cross-adsorbed Alexa488 (Invitrogen). The cells reacted with the antibody were measured using a FACS Aria III (Becton, Dickinson and Company). The obtained data were analyzed using FlowJo ver.10. The cells were separated into a fraction stained with CellTrace FarRed (empty plasmid vector-transfected cells), an unstained fraction (human NOX1-Strep-transfected cells), and a fraction stained with CellTrace FarRed and CellTrace Violet (NOX1_Nx1B_564-myc-transfected cells), and Alexa488 staining for each fraction was confirmed. The unstained fraction (human NOX1-Strep-transfected cells) and fractions stained with CellTrace FarRed and CellTrace Violet (NOX1_Nx1B_564-myc-transfected cells) showed predominant staining compared to the fraction stained with CellTrace FarRed (cells transfected with an empty plasmid vector) (FIG. 11). From this, it was confirmed that the anti-human NOX1 antibody prepared in Example 13 binds to human NOX1 expressed in cells.
[0247] The foregoing invention has been described in detail by way of illustration and example for purposes of facilitating a clear understanding, but the descriptions and illustrations herein should not be construed as limiting the scope of the disclosure. The disclosures of all patent and scientific literature cited herein are expressly incorporated herein by reference in their entirety. [Industrial Applicability]
[0248] The antibodies of the present disclosure have at least one of cytotoxic activity and internalizing activity, and are useful for either or both of the treatment and prevention of cancer (eg, lung cancer, colon cancer).
Claims
[Claim 1] The invention described herein.
